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CHAPTER I 
INTRODUCTION 
I 'Pl y:::t'NA ~ 1> 
L!1-=-~urpo~-~--<?!_ .. t~~.~- ~~-~~--~~---=~~~~~~~~;:~~~5=s~ 
from the standpoint of t~~- . .;on·~-~~-~ng ~~~n.._c!.i:~li..!l8.., with nursing home 
-----·---·--·--· ------··"--·-~·----·~ ....... ~---······-·---···-····-·-·-------·----------- .................... . 
· residents·) Nursing home residents may be old or sick or both. It is . 
,..--------- ....................... ., ........... -·····•"'''''''"''"·-···-··· . ····---................ ...• .. ·-'····..... ..................... .............. ................... . .. . 
often difficult to detect by appearance a drug-nutrient interaction be-
cause the older person's appearance is already altered due to age. The 
emotional state of the older patient may contribute to this change due 
to a feeling of no longer being wanted or useful and this in turn may 
affect his or her appetite. Many times the older patient prefers des-
serts to protein foods. They are easier to chew and have a sweet taste, 
which may appeal to the older individual. In dealing with drug-nutrient 
interactions, the importance of proper nutrients and adequate fluids can-
not be underestimated in that the older patient is often the one who is 
taking large amounts of drugs. 
Becoming aware of drug-nutrient interactions will require the com-
bined effort of both the dietitian and the pharmacist. The dietitian is 
often not familiar with the many drug categories and tr.ad~ names and the 
------pharmacist is often unfamiliar with nutritional implications .. of <l,rl1~ .. 
usage. The combined efforts of the pharmacist and the dietitian plus 
~~---
proper charting of those efforts will aid the physician, in treating the 
patient, to be aware of specific problems. 
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The objectives of this study were: 
1. to determine the number and kinds of drugs prescribed and the 
time of administration for approximately 200 nursing home patients, 
2. to relate the drugs being used to drug-nutrient interactions 
reported in the literature, 
3. to assess aspects of nutritional status of subjects through 
determination of several health related factors, and 
4. to make recommendations regarding health care of patients in 
nursing homes based on these findings. 
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CHAPTER II 
REVIEW OF LITERATURE 
Drug Absorption and Metahol-i..sm 
, .. ---~---~ 
--------
Goodman and Gilman (1) define a drug as any chemic~! agent that 
---- ,__ -- - ---
affects living processes. Ma!._!:in_ (2), in Hazards of Medication, defines 
,...--- ------------ - , _ -- --- -----
a drug as a physiologically act~~u~stance_~se~ f_or _diagnosis, preven-
- · tion or treatment of disease. A dictionary definition is a chemical 
- - -
substance administered to a person or animal to prevent or cure disease 
or otherwise enhance physical or mental we~.f-~n::_~ _ _(J). Martin (2) states: 
••• there are no harmless medications. All are potentially 
hazardous to some extent and all must be prescribed and admin-
istered with caution. Otherwise, patients may be seriously 
injured (p. 17). 
In order to produce its intended effects, a drug must be present at 
its site of action in the proper amount. This involves the amount of 
- ---
drug administered. It also involves how the drug is absorbed and 
.------
distributed. Five factors which influence efficacy of a drug are: 
--
1~6rm-~The drug is an appropriate biologically active form 
(salt, ester, ether, metabolite or other derivative). 
2. Place--The drug reaches the appropriate site of drug ac-
~tion in the patient (gastrointestinal or urinary tract, 
blood, lymph or specific cells, tissue, organ or system) 
and therefore the drug must be suitably released from 
its dosage form and absorbed and delivered to the site 
of action within an appropriate period of time. 
3. Quantity--The drug permeates that site in an appropriate 
concentration in an unbound pharmacologically active 
form. 
4. l'ime--The drug remains at that concentration for an ap-
___ /' propriate length of time by controlling input (gastro-
intestinal, parenteral or dermatomucosal) to off set the 
3 
output (metabolic destruction and excretion). 
~espofise--The patient responds to the drug in an appro-
priate manner (2, p. 17). 
The absorption of drugs is involved with the passage of a drug 
4 
across cell membranes. Drugs generally pass through rather than between 
cells. Thus, the common barrier is the cell plasma membrane. The cell 
membrane is composed of proteins and lipids (1). The postulated struc-
ture is a central layer of lipids covered on either side by protein 
(Figure 1). The presence of protein on the surface supposedly makes 
water adhere easily to the membrane. The lipid or fat center makes the 
membrane impermeable to fat-insoluble substances. The lipids are about 
65 per cent phospholipids, 10 per cent other lipids and 25 per cent 
cholesterol. The small knobbed structures are phospholipid molecules. 
The fat portion of the phospholipid molecule is dissolved in the lipid 
part of the cell membrane and the polar (ionized portion) projects out-
ward with the protein lining the outer surface of the membrane (4). 
Drugs cross cell membranes by passive processes, active transport, 
or pinocytosis (1). Active transport is a mechanism in which enzyme 
systems and special carrier substances carry the substance through the 
membrane (4). Passive processes refers to the simple process of dif-
fusion (4). Pinocytosis is a process which causes the cell membrane 
to first turn back within itself and then to pinch off inside the cell 
to form a pinocytic vesicle. The pinocytic vesicle either dissolves 
inside the cell and discharges the contents into the intracellular space 
or combines with digestive enzyme~ before distributing them intracel-
lularly (4). 
---------·------· -
PflOTEIN LIPIDS PROTEIN 
···-·- .. ------ -"--------,,- ...... --. 
A 
Source: 
Figure 1. 
Pores 
81 
8 
Arthur C. Guyton, Func-
tion of the Human Body 
(1969). 
Cell Membrane--(A) 
Postulated Molecular 
Organization of the 
Cell Membrane, (B) 
Pores in the Cell 
Membrane· 
, 
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Absorption of drugs is affected by many variables. One variable is 
drug solubility. A drug given in solid form is not absorbed as readily 
as one given in solution. Conditions at the site of absorption affect 
solubility. Acidity is an important alkalinity variable. Acidic drugs 
tend to precipitate in the stomach fluids if the pH of the gastric juice 
is low. Dissolution then occurs very slowly. Drugs given in solutions 
of high concentration tend to be absorbed more rapidly than drug~ in 
low concentration (2). 
Absorption of a drug is increased or slowed by blood circulation 
at the site of absorption. If circulation is slow due to decreased 
blood flow, absorption is slow. If circulation is increased, such as 
by massage or local application of heat, absorption is more rapid (2). 
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The size of the area of the absorbing surf ace is important in 
absorption of a drug. Large surface areas cause the drug to be absorbed 
more rapidly (2). The absorbing surface is determined mostly by the 
route of administration. The oral route has been used for the longest 
period of time and is also the safest, most economical and most con-
venient. There are some disadvantages to the oral route of ingestion. 
These include vomiting which may be caused by irritation of the gastro-
intestinal mucosa of the drug. Some drugs may be destroyed by the 
digestive emzymes. Other drugs combine with food to form substances 
that cannot be absorbed. Using the oral route of drug administration 
also means the patient must cooperate in taking and swallowing the 
drug (1). 
If gastric emptying time is retarded, drug absorption may be re-
-····- ... ~- --
duced. The small intestine provides a large surface area for absorption 
of a drug. If the drug is held in the stomach due to delayed gastric 
__ ---------.,k 
emptyin;\i~, absorption of the drug will be slowed because of the 
longer time before reaching the larger surface area of the intestine. 
Ingestion of food at the same time a drug is given will delay absorption 
time (1). 
Sustained release pharmaceutical preparations are based on the 
factor of the dissolution rate in gastrointestinal fluids. Tablets 
within tablets, pellets in capsules, slowly dissolving salts in solids, 
provide a drug effect for eight hours or longer (1). 
Drugs may also be given by ~njection. 1 Absorption may be more pre-
dictable and more rapid. The dose which would be effective could be 
more accurately selected. It is necessary to give drugs by injection if 
the patient is vomiting and unable to retain the drug by mouth, or is 
7 
unconscious. The disadvantage of giving a drug by injection includes 
pain for the individual, strict asepsis must be followed to avoid infec-
tion and the patient cannot perform the injection himself (1). 
Certain areas of the body serve as drug storage sites. Plasma 
proteins are one storage depot outside the cell. The binding is usually 
to albumin. Other plasma proteins can also bind drugs if the albumin is 
saturated and cannot bind any additional amount of a drug or drugs. The 
amount is dependent on the kind of drug involved. If phenylbutazone is 
given, binding may be as high as 98 per cent. If antipyrine is given, 
binding may be practically nil. If the drug has an affinity for albumin, 
the albumin may serve as a large storage depot. Some drugs are bound to 
ionic groups for the mucopolysaccharides and are stored in connective 
tissue. Bone may act as a storage for heavy metals and tetracylines 
(1). 
Some drugs accumulate in cells. Active transport systems may be 
involved in drug storage within a cell. The binding within a cell oc-
curs with tissue constituents such as nucleoproteins, phospholipids or 
proteins. This process is usually reversible, since almost all drugs 
finally disappear from the body. One example of a drug which is stored 
in the cell is quinacrine (an antimalarial agent). Four hours after a 
single dose, the liver concentration is 2,000 times greater than the 
plasma level. If the drug continues to be administered the liver ac-
cumulation may amount to 22,000 times the plasma level (1). 
Many drugs are stored in the solid fat since they have a high lipid 
solubility. If an individual is obese, the fat content of the body may 
be as high as 50 per cent. Even in starvation, fat makes up 10 per cent 
of the body weight. In some instances, three hours after administration, 
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as much as 70 per cent of a highly lipid soluble drug may be present in 
body fat. 
Drugs may accumulate in the gastrointestinal tract. If a drug is 
not very soluble in gastrointestinal fluids, it will be absorbed slowly. 
This will prolong the length of t1me the drug is in the body (1). 
The cerebrospinal fluid does not generally store drugs since there 
is no protein present for binding (1). 
The thyroid serves as a storage area for iodine and can also store 
some drugs such as perchlorate and other ions. 
Drug effect is usually terminated by biotransf ormation and then 
excreted from the body. A drug may also be redistributed from its site 
of action. If it is distributed to other tissues, it is stored in 
active form and must still have its effects terminated by the usual 
means (1). 
Two reactions by which biotransformation of drugs occurs are clas-
sified as synthetic and nonsynthetic. The nonsynthetic include oxida-
tion, reduction or hydrolysis. The synthetic reaction is also called 
conjugation. This means a coupling between the drug and its metabolite 
plus a substrate in the body such as a carbohydrate or an amino acid. 
Drayer (5, p. 927) states drug metabolism usually takes place in 
two steps: 
_ ...... ---------
Phase I 
Drug,.· > 
_/'enzymes 
{
Oxidation 
Reduction 
Hydrolysis 
Metabolites 
Phase II 
enzymes 
Conjugated_· 
metabolites 
Groups such as OH, co2H, and NH2 are added to the drug molecule in 
step one. The metabolite reacts with a substrate in the body in step 
two, such as an amino acid or glucoronic acid, which results in a 
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conjugated metabolite that is usually excreted from the body. Cohen 
(6, p. 2) shows this reaction with the following diagram: 
Glucuronic Acid 
S b Glucuronide u stance--Complex 
(inactive) 
Substance 
Glucuronyl Transferase 
If the drug is lipid soluble, the portion reabsorbed in the kidney 
tubule cells by diffusion is greater than if the drug is not lipid 
soluble (5). 
The main site for biotransformation of drugs is in the liver. Some 
may occur in the plasma or kidneys. The enzyme system involved in the 
liver is located in the endoplasmic reticulum of the cells. More specif-
ically, activity seems to occur in the microsomes (1). Microsomes are 
minute corpuscles embedded in the protoplasm. Great numbers of these 
corpuscles contribute to the granular appearance of protoplasm (3). The 
microsomal enzymes cause the reactions to occur for both synthetic and 
nonsynthetic biotransformations (1). 
The endoplasmic reticulum extends through the cell like a canal 
system (Figure 2). 
The endoplasmic reticulum may transport substances within the cell. 
Through the electron microscopy small ribonucleoprotein particulaes, 
which are called "palade granules" have been identified. These cause the 
endoplasmic reticulum to have a rough surface. The rough surface 
microsomes are thought to be concerned with protein synthesis. Only the 
smooth surface microsomes have enzymes that metabolize drugs. Drugs 
must be lipid soluble to be metabolized by liver microsomes. Some 
microsomal enzymes change lipid soluble substances to more water soluble 
substances (1). 
Neutral fat -- -
llqrof'lulor @ndjtPlosrmc __ 
ret1cu lum 
Source: Guyton, Function of the 
Human Body (1969). 
Figure 2. Organization of the 
Cytoplasmic Compart-
ment of the Cell 
Many things seem to affect the activity, structure and amount of 
smooth surfaced or drug metabolizing microsomes of the endoplasmic 
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reticulum. Some of these are age, sex, temperature, nutritional status, 
stress or strain, pathological status, various drugs and hormones (1). 
Observations have been made that a drug can stimulate its own 
metabolism or can stimulate the metabolism of another drug. The pharma-
cological effects of a second drug or second dose can be modified by the 
first drug or first dose since its metabolism can be affected by stimula-
tion of the drug-metabolizing enzymes. The following diagram shows how 
the interaction may occur (1) (Figure 3). 
Excretion of Drugs 
The orgfl_n in the body of most importance for drug excretion is the 
Drug I 
(activity desired) 
Liver 
(metabolism 
/ 
Drug II induced liver to 
produce a greater number 
of drug metabolizing 
enzymes (enzyme i~tion) 
Increased metabolic 
rate of Drug I 
\ 
Decreased effects of 
Drug I {antagonism) 
I 
Increased effects of Drug I 
due to an active metabolite 
(not dependent on enzyme 
system) 
site) 
Drug II 
(comes on scene) 
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~ 
Drug II may compete with 
Drug I for the same metab-
olizing enzymes (competi-
tive inhibition) 
I 
Decreased metabolic 
rate of Drug I 
I 
Increased effects of 
Drug I (potentiation) 
Source: M. S. Cohen, Drug Metabolism Class Notes. 
Figure 3. Pathways of Interaction 
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kidney. Some drugs may be excreted in the feces if they are not absorbed 
in the digestive tract. Some drugs are eliminated from the body un-
changed, some are eliminated as metabolites. The drugs which are elim-
inated unchanged are usually the more polar compounds. The drugs which 
are lipid-soluble and less polar are usually not eliminated until they 
are metabolized to be more polar. Only non-ionized or unchanged parts 
of a drug cross the lipid-like membranes of the cells in the kidney. 
Drug molecules are filtered at the glomerulus in the kidney and return 
to the blood stream by diffusion across the tubular cells. If compounds 
are more polar they cannot penetrate the membrane and so they are given 
off in the urine. Transfer of molecules across the membrane of the cell 
are pH dependent. If pH of the luminal fluid is changed, the excretion 
of the drug is influenced (1). 
Three processes are involved in the excretion of drugs: (1) pas-
sive glomerular filtration, (2) active tubular secretion, and (3) passive 
tubular diffusion (1). Drugs which are organic acids may be moved 
through the body by the same system that transports substances like uric 
acid. Organic bases may be transported in the body by a system which 
takes care of naturally occurring bases in the body (1). 
Weak acids and bases in non-ionized forms are reabsorbed or 
execreted by passive diffusion. Passive diffusion can be bidirectional. 
Drugs can diffuse in either direction across tubular cells, this de-
pends upon the pH and the concentration of the drug. The excretion of 
a drug can be increased by changing the alkaline or acid content of the 
urine. The weak acids are excreted slower if the urine is more acid 
than plasma. The weak acids are excreted faster if the urine is more 
alkaline than plasma (1). 
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Some metabolites which have been formed in the liver are excreted 
via the bile. This may result in the drug being excreted in the feces 
but usually the drug is reabsorbed into the blood and then is excreted 
via the urine (1). 
When discussing drugs, the terms "action" and "effect" have differ-
ent meanings. Drug effects are produced by combining with enzymes or 
cell membranes. The action of drugs is related to the chemical struc-
ture. The chemical structure of a drug may have a minor modification 
which can result in a major change in pharmacological properties (1). 
Drugs may act on particular cells or organs and produce a localized 
effect. Other drugs can have very general effects and act in or on most 
cells of the body. Drugs can also produce effects by increasing or de-
creasing the action of another substance in the body (1). 
Drug effects may differ with one patient as compared to another 
patient. A drug may differ with even the same patient on different 
occasions and under different circumstances. All drugs produce some 
effect. The margin of safety of a drug is determined by the relation-
ship of the desired effects versus the undesired effects (1). 
Factors Which Predispose a Patient 
to a Drug Interaction 
Many factors may influence an individual to a drug interaction • 
• -· ><.Y••• --
Some of these factors originate in the individual and others are related 
to the drug or drug prpduct (8). Some of these factors are discussed 
..---------·---··---·--------- --··• 
in the following paragraphs• 
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Age is an important factor in that studies show there is increased 
dangerofB.Overse drug reactions in the geriatric individual and in the 
very young. The risk of a drug reaction is almost double in adults 60 
to 70 years of age as compared to adults 30 to 40 years old (8). 
Gastric secretion may be lower in older individuals. Goodman and 
Gilman (1) suggest one-third of older persons between 60 and 90 years of 
age may have achlorhydria. This affects certain drugs which are usually 
destroyed to a significant degree by gastric acid. As an example, 
penicillin G is usually destroyed to a significant degree by gastric 
acid and the result will be that penicillin is likely to have a greater 
effect in older people. Low gastric acid secretion may also be present 
during the first month of life (8). 
Renal function may be slowed with age. This may result in a drug 
that would ordinarily be excreted accumulating in the body with possible 
toxic effects (8). Rosenberg and Mann (7) report one study of 35 elderly 
patients in which 46 per cent had reduced renal function, even though 
they did not have a kidney disease. The suggested cause was vascular 
insufficiency to certain areas of kidney tissue which results in reduced 
tubular function. When the glomerular filtration rate is decreased, the 
half-life of many drugs is increased. It is, therefore, necessary to 
decrease ·the dosage of the drug to prevent toxicity. 
One study concerning digoxin compared blood levels and urine 
excretion levels of elderly men between 73 and 81 and men between 20 and 
33 years of age. It was found the older men had blood levels of digoxin 
nearly double that of the younger men (7). 
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Factors which accentuate toxic effects of drugs in the infant are 
listed by Rosenberg and Mann (7) as follows: 
1. Drug enzyme processes are immature or not formed. 
2. There are different absorption, distribution and excre-
tion patterns. 
3. Immature tissues respond to drugs differently than mature 
tissues. 
4. Drugs in this age group alter distribution of naturally 
occurring substances of the body, such as hormones and 
bilirubin, in a manner that does not occur in other age 
groups. 
5. Drugs actually alter a developmental process that is 
occurring. In infants, oxidative pathways are deficient, 
particularly mocrosomal enzymes which metabolize drugs, 
e.g., barbiturates, acetanilid, amphetamines, codeine, and 
chlorpromazine. Reductive processes are less deficient 
and hydrolytic reactions are the least deficient in the 
newborn compared to the adult (p. 34). 
One example of a drug which may produce death in an infant is 
chloramphenicol. The drug is detoxified by glucoronide formation but 
the young lack the enzyme glucoronyl transferase which forms glucoronide 
(7). 
The blood brain barrier in infants is poorly developed. Some drugs 
displace naturally-occurring bilirubin from its bound form. Examples of 
these are salicylates and sulfonamides. The free bilirubin will pass 
through the blood brain barrier since it is poorly developed. The re-
sult can be degenerative changes that would not happen to an older child 
who has a developed blood brain barrier (7). 
_Tetracyclines cause discoloration or other damage to the teeth in 
young children if they are given when teeth are being formed. It is 
recommended that use of the drug be avoided during th~ first half of 
pregnancy, infancy and up to the age of eight (8). 
Individual Differences 
Different individuals metabolize drugs at different rates. Factors 
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which can vary with the individual patient are pH of the fluids, bile 
flow, gastric emptying time, volume and composition of gastrointestinal 
fluids, intestinal mucosal surface area (7). 
Hussar (8) states that some drugs can be metabolized by different 
individuals at widely varying rates. One example is the coumarin anti-
coagulants such as warfarin and bishydroxycoumarin. Resistance to 
warfarin has been shown to be related to genetic variations. 
Another inherited characteristic is a deficiency of the enzyme 
glucose-6-phosphate dehydrogenase. This appears more frequently in 
black persons, especially male, and among ethnic groups of the Mediter-
ranean area. When drugs such as primaquine, phenacetin or sulfonamides 
are given to such individuals hemolysis can develop, causing a hemolytic 
anemia (8). 
Ethnic Background 
Black people seem to be more susceptible to hypertension. Anti-
,hypertensive therapy may be more likely to result in a drug interaction 
since hypertension is likely to develop at a young age and frequently be 
more severe (8). 
Weight 
It is recommended drug dosage be adjusted according to body weight. 
A person weighing 100 lbs. would need a smaller dosage than an individual 
weighing 220 lbs. The ratio between the body weight and the amount of 
drug administered generally influences the concentration of the drug at 
its site of action. However, if the body weight of an obese person is 
the same as that of a muscular football player, a problem would develop 
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since many drugs are distributed in the water and lean mass and not in 
the fat. For example, the same dosage of a drug, such as digoxin, would 
act differently. The obese person may develop a toxicity, as there 
would be a higher concentration of drug at the site of action. It is 
possible that women have a higher incidence of drug reaction than men 
because of the difference in weight, lean mass and subjective response 
(7). 
Temperament 
Easily excitable, nervous and unstable individuals require smaller 
amounts of s~imulants and larger amounts of depressants. On the other 
hand slow, sluggish individuals require large amounts of stimulants and 
smaller amounts of depressants. Individuals who are neurotic, sensitive 
and high strung report more placebo reactions and have a tendency to 
experience more actions and reactions from medications (7). 
Ren·a1 Function and Liver Function 
Hussar (8) states the renal status of a patient should be known, 
particularly if the drug is primarily excreted by the kidney. In one 
study the adverse reactions in patients with impaired renal function 
were two and one-half times that of patients with normal renal function 
(9). A prolonged effect is seen if there is renal impairment and as 
additional doses are given, the blood levels will increase resulting in 
toxicity. 
Only the portion of a drug in the blood bound to plasma proteins is 
available for glomerular filtration. Any agent that alters the protein 
binding may alter its filtration rate. If a second drug displaces plasma 
protein binding sites, there is an increased amount of "free" drug 
present and the filtration rate will increase (8). 
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Urinary pH may alter activity of some drugs. One example is the 
administration of sodium bicarbonate with the older, less soluble 
sulfonamides to provide a more alkaline urine in which the drugs and 
their metabolites are more soluble, thus reducing the risk of crystal 
formation. The pH of the urine will influence the ionization of weak 
bases and weak acids and affect the extent to which drugs are reabsorbed 
or excreted. If the drug is in its non-ionized form it will more readily 
diffuse back into the blood from the urine. Erythromycin and Novobiocin 
are generally thought to be effective against gram-positive organisms. 
If the pH is made more alkaline, they may also be effective against a 
number of gram-negative bacterial infections (8). 
Metabolism of drugs is concentrated in the liver. It is a triple 
system which consists of an uptake system (Y and Z proteins), an oxygen 
insertion system centered on cytochrome P-450, and a conjugation system. 
This triple system is adapted to removal of foreign compounds. Albumin 
transports lipophilic molecules, and the biliary apparatus secretes con-
jugated drugs into the bile. Drug metabolism is not a single entity but 
a family of enzymatic processes (14). 
If there is hepatic damage, drugs may be metabolized at a slower 
rate and exhibit a prolonged effect. Some drugs may alter the amount 
or activity of the liver microsomal enzymes. Some substances are known 
to stimulate the activity of liver microsomal enzymes. The result is a 
more rapid metabolism and excretion of a drug. For example, pheno-
barbital stimulates the activity of liver enzymes which can then in-
crease the rate at which warfarin is metabolized. The result is that 
warfarin is more rapidly excreted resulting in a decrease in anti-
coagulant activity. The opposite effect could occur where one drug 
inhibits the activity of liver enzymes, which could prolong and in-
tensify the effect of other drugs (8). 
Protein Alteration 
Many drugs are extensively bound to plasma proteins, only the un-
bound fraction of a drug is active. A dietary reduction of either 
quantity or quality causes a depression of hepatic microsomal mixed 
function oxidase activities. In persons whose dietary protein is low, 
the availability of drugs and thus their activity could be affected 
(11) (12) (13) (14). 
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In the ill, the binding of drugs to serum proteins can be different. 
When a pathological condition exists albumin may be reduced which may 
decrease the number of drug binding sites available (7). 
Smoking 
Jick (10) provided evidence that smokers behave differently than 
non-smokers when certain drugs are given. The data reinforced the 
hypothesis that cigarette smoke induces certain liver microsomal enzymes 
which increase the metabolism of some drugs. One drug studied was 
propoxyphene, a widely used oral analgesic. The drug was rated inef-
fective in 10.l per cent of non-smokers, 15.0 per cent of light smokers 
and 20.3 per cent of heavy smokers. Another group of drugs studied were 
the benzodiazepines. There was a strong association between adverse 
reactions to diazepam and chlordiazepoxide and smoking. Adverse reac-
tions were correlated wit4 age and dose. 
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Environmental Factors 
Liver microsomal enzyme activity may be increased by trace amounts 
of DDT and chlordane in foods which would significantly increase the 
metabolism of many drugs. The organic phosphorus insecticides may 
inhibit the hydroxylation of drugs by affecting liver microsomes (7). 
Sunlight can be an environmental factor. Some drugs in combination 
with sunlight may increase the individual's susceptibility to dermatitis. 
These drugs are potent photosensitizers: barbituates, diuretics, certain 
steroids, tetracyclines, Dilantin, certain antidepressants, and the 
phenothiazines (7). 
The temperature in different climates has an effect on drug reac-
tions. In tropical climates, preliminary excitement and delirium are 
more readily produced by narcotics. Increase in temperature increases 
the rate at which drugs are metabolized and excreted. Temperature 
modifies individual response to drugs by effecting the intensity of 
sensory stimulation (7). 
Lower body temperature decreases neuromuscular blockage produced by 
succinylcholine. The phenothiazines are more depressant at 13 to 18° C 
as compared to 25 to 30° C (7). 
High altitude with associated oxygen deprivation increases sensitiv-
ity to many agents. Increased dosages of barbituates are necessary when 
there is intense noise of long duration. Crowding or isolation alters 
the response to drugs (7). 
Diet 
The body's adaptation to low energy and protein intake causes pro-
found biochemical change. If protein is deficient, the body conserves 
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nitrogen by increased recycling of amino acids resulting in decreased 
urea formation. In this manner, nitrogen balance may be achieved but 
if the individual develops an infection, the balance is easily upset. 
Drugs which antagonize protein synthesis may also upset the balance. 
When energy intake is deficient, energy is provided by a breakdown of 
body proteins. 
Clinical malnutrition may increase with infection and nutritional 
anemia ( 11) . 
Basu and Dickerson (12) state secondary malnutrition commonly re-
sults from some disease states. In developing countries where there is 
a shortage of food,primary malnutrition is common. Malnourished subjects 
are treated with drugs and both the drugs and the disease may effect 
metabolic processes. The metabolism of the drugs may be altered by the 
patient's nutritional status. The drugs themselves may change the re-
quirement for particular nutrients. 
Campbell and Hayes (13, p. 171) discuss the role of nutrition in 
the drug metabolizing enzyme system. They state "experiments with both 
adequate and deficient diets have shown impressive differences in the 
activities of drug metabolizing enzymes." Most of the information 
concerning diet and drug metabolizing enzymes has been from animal 
studies rather than clinical data. The lack of clinical data on drug 
and nutrition interaction may be based on the following: 
1. The separation of cause and effect for the toxicity may 
be far removed in time. 
2. The information on pathological symptoms characteristic 
of environmental toxins is not yet complete. 
3. The expected systems are rather subclinical, nondescript 
and chronic in nature (13, p. 171). 
Diet may affect the gastrointestinal ~bsorption rate and con-
sequently the concentration of certain drugs in the blood. As an 
example, tetracycline and penicillin derivatives should be given one 
hour before or two hours after meals for optimal effect. Milk and 
-other dairy products which contain calcium may decrease the absorption 
22 
of tetracycline derivatives by formi~g a complex with them in the gastro- · 
intestinal tract (8). 
If tetracyclines and milk are given together, plasma levels of 
the antibiotic only reach 19 to 75 per cent of what should be expected. 
Tetracyclines inhibit protein synthesis in man. They should not be used 
in renal failure. Tetracyclines can cause negative nitrogen balance in 
patients with normal renal function. Normal clinical doses of tetra-
cyclines may inhibit the utilization of amino acids for protein 
synthesis. Prolonged use of tetracyclines must be considered in post-
operative and injured patients who require effective tissue rebuilding 
(15). 
Drugs may be.mixed with various juice and beverages to try to 
mask unpleasant taste or to assist patients who have difficulty swallow-
ing. This is especially true in the pediatric or geriatric patient. 
Mixing drugs with juices may precipitate a problem with acid labile 
substances where absorption might be impaired in the stomach because of 
decreased gastric pH or inactivation in acid media. Acid labile 
antibiotics such as ampicillin, erythromycin base and penicillin G 
potassium should not be mixed or allowed to stand in the beverages listed 
in the following table. The ingestion of large volumes (in excess of 
eight ounces) of such beverages with any acid labile substance should be 
avoided whenever possible (16). 
It is generally thought that extreme shifts in urinary pH (well 
below 5 and 8) are difficult to achieve by dietary patterns alone. 
TABLE I 
pH RANGE OF SELECTED COMMERCIALLY CANNED 
JUICES AND OTHER BEVERAGES 
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Juices and Beverages Approximate pH Range 
Canned Juices 
Cherry 3.4 - 3.6 
Cider 2.9 - 3.3 
Cranberry 2.5 - 2.7 
Currant 3.0 
Grapefruit 2.9 - 3.4 
Grape 3.5 - 4.5 
Lemon 2.2 2.6 
Lime 2.2 - 2.4 
Pineapple 3.4 - 3.7 
Prune 3.7 - 4.3 
Tomato 3.9 - 4.4 
Other Beverages 
Milk (cow's) 6.4 - 6.8 
Milk (evaporated) 5.9 - 6.3 
Beers 4.0 - 5.0 
Wines 2.3 - 3.8 
Source: P. G. Pierpaoli, Drug Therapy and Diet, Drug Intel. Clin. 
Pharm. (1972). 
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TABLE II 
APPROXIMATE pH OF CARBONATED BEVERAGES 
Beverages pH 
Club soda 4.7 
Cream soda 3.9 
Cherry soda 3.0 
Cola 2.4 
Ginger ale (pale dry) 2.7 
Grape 3.0 
Grapefruit 3.0 
Lemon 2.9 
Lemon-lime 3.1 
Orange 3.2 
Quinine 2.5 
Raspberry 3.1 
Root beer 4.0 
Sarsaparilla 4.0 
Source: Pierpaoli, Drug Intel. Clin. Phann. (1972). 
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However, urinary changes have been observed with ingestion of acid-ash 
or alkaline-ash diets and urinary acidifying or alkalinizing drugs. 
Urinary pH can have clinical significance, one cited case was caused by 
ingestion of antacids, an alkaline-ash diet and quinidine causing 
quinidine intoxication. The patient was consuming eight tablets daily 
of an antacid preparation containing 200 mg. of magnesium, 20 mg. of 
simethicone, 200 mg. of dried aluminum hydroxide gel. He was also con-
suming one quart daily of fresh orange-grapefruit juice (1:1 ratio). 
The fruit juice mixture would be equal to about 50 mEq. of bicarbonate 
ion daily. The combination of an excessive alkaline-ash diet intake 
plus antacid therapy produced a consistent alkaline urine with a result-
ing decrease in quinidine excretion. The patient developed a serious 
abnormal sinus rhythm requiring hospitalization (16). 
~---
A strict vegetarian diet or excessive and chronic use of alkaline-
ash foods could more than likely produce alkaline urine. Tables III and 
IV show examples of acid-ash foods and alkaline-ash foods. This should 
be considered in drug histories with patients receiving acidic or 
alkaline drugs. Excretion may be altered by changes in urinary pH which 
could result in drug toxicity (16). 
Time of Administration 
Time of administration of a drug is also of importance to the 
patient. The following table (Table V) has been compiled by Milne (15). 
Shore (17) compiled an extensive table of drugs by both non-
proprietary and trade name. The tables list times to take the drug in 
relationship to other foods and antacids. 
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TABLE III 
POTENTIALLY ACID OR ACID-ASH FOODS 
Meat 
Meat, fish, fowl, shellfish 
Eggs 
Cheese (all types) 
Peanut butter 
Vegetable 
Corn and lentils 
Fruit 
Cranberries, plums, prunes 
Fat 
Bacon 
Nuts (Brazil, filberts, peanuts, 
walnuts) 
Bread 
Breads (all types), crackers 
Macaroni, spaghetti, noodles 
Dessert 
Cakes and cookies, plain 
Source: Pierpaoli, Drug Intel. Clin. Pharm. (1972). 
TABLE IV 
POTENTIALLY BASIC OR ALKALINE-ASH FOODS 
Milk, cream and buttermilk 
Nuts 
Almonds, chestnuts, coconut 
Vegetables 
All types (except corn and 
lentils) 
Fruit 
All types (except cranberries, 
prunes, plums) 
Source: Pierpaoli, Drug Intel. Clin. Pharm. (1972). 
TABLE V 
TIMES TO TAKE DRUGS 
Drugs to be taken on an empty stomach (one hour before or three hours 
after meals) 
Ampicillin Phenmetrazine 
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Erythromycin base drugs 
Penicillin G (ammonium and 
Tetracycline and its derivatives 
potassium) 
Triethylene melamine 
Oxacillin 
Lincomycin 
Triacetylolcandomycin 
except doxycycline 
Sulfonamides 
Sulfisoxazole 
Sulfadimethoxine 
Drugs to be taken one-half hour before meals 
Atropine Sulphate 
Belladonna Tincture 
Phenobarbitol and Belladonna 
extract 
Drugs to be taken immediately before, with or immediately after meals or 
with food or drink 
Aspirin 
Chloropropamide-Chloramide 
Chlorinase 
Diabinase, Stabinol 
Ferrous fumerate-Ferroton, 
Ferrofume, Fernamel, Fumiron, 
Irofum, Novofuma, Palifer, 
To lifer 
Other ferrous compounds 
Phenoformin 
DBI 
Potassium Drugs 
Prednisone 
Tolbutamide 
Drugs not to be taken with milk or milk products 
Potassium chloride tablets and 
solutions 
Potassium iodide 
Tetracyclines and its derivatives 
Biscacodyl (Ducolax) 
Digitalis 
Digoxin 
Drugs not to be taken with fruit juice (Fruit juice is acidic and may 
cause premature breakdown of these acid labile drugs, or the juice may 
increase the urinary excretion of the drug. This includes all juices, 
beer, wine, and soft drinks.) 
Ampicillin 
Erythromy~in base drugs--E-mycin 
Erythromycin, Llotycin 
ASA and other salicylates 
Las ix 
L-Thyroxin 
TABLE V (Continued) 
Drugs not to be taken with fruit juice (Continued) 
Penicillin G (ammonium and 
potassium) 
Atropine 
Aldomet 
Demerol 
Elavil 
Neg Gram Tabs (Nalidixic acid) 
Quinidine 
Warfarin 
Amobarbitol 
Benadryl 
Drugs absolutely contra-indicated with alcohol 
Apresoline 
Chloral hydrate 
Codeine 
Chloromycetin 
Compazine 
Darvon 
Dilan tin 
Demerol 
Diuril 
Elavil 
Flagyl 
Forhistol 
Guanethidine 
Hydrodiuril 
Insulin 
Drugs not to be taken with antacids 
Bisacodyl 
Ferrous gluconate, lactate 
Succinate 
Sulphate 
Drugs not to be taken with mineral oil 
All vitamin preparations 
Las ix 
Librium 
Morphine 
Meprobamate 
Nitroglycerine 
Neg Gram Tabs 
Seconal 
Quinol 
Tetracyclines 
Valium 
Natulan 
Procarbazine 
Methyl hydrazine 
Tolbutamide 
Ferrous Fumerate 
Tetracyclines and all its 
derivatives 
Foods high in pressor amines should not be eaten while taking these 
drugs and should not be eaten for three weeks following cessation of 
the drug 
Tranylcypromine (Parnate) 
Isocarbazid (Marplan) 
Nialamide (Niamid) 
Morphine 
Phenylzine sulphate (Nardil) 
Natulan 
Amphetamines 
Procarbazine 
Digitalis and digitalis 
· glycosides 
Methyl hydrazine 
Phenylephrine (neo-synephrine) 
Guanethidine 
Insulin 
Reserpine 
Furazolidone 
Isoniazid 
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TABLE V (Continued) 
Drugs not to be taken with vitamins 
Anticoagulants and vitamin C 
Anticoagulants and vitamin B complex 
Vitamin C SHOULD be taken with ferrous compounds as they are better 
absorbed in the presence of ascorbic acid. 
Source: A. A. Milne, Food and Drug Interactions, J. Can. Dietet. A. 
(1973). 
Drug-Nutrient Interactions 
Drugs are one class of a group of substances which are of no 
nutritive value and are chemically foreign to the body. This group of 
substances are known as xenobiotics, anutrients or foreign compounds. 
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Anutrients include food and cosmetic additives such as benzoic acid, azo 
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dyes- and butylated hydroxytoluene; natural anutrients in foods such as 
alkaloids, flavonoids, ethers; food contaminants such as pesticides and 
industrial chemicals (12). 
Chemicals normally regarded as foreign to the body are metabolized 
by a group of non-specific enzymes located in hepatic microsomes. These 
are referred to as "microsomal drug metabolizing enzymes" (12). 
~ierpaeoli (16) categorizes pharmacologically active substances 
present in foods: 
1. Foods of Plant and Animal Origin 
-In this class, one can cite the presence of 5-hydroxy-
tryptamine in ...Qin.eapples and bananas, 3-4-dihydroxy-
phenylalanine (DOPA) in _proad beans, oxalates in spinach, 
rhubarb and celery. Various metals such as selenium, 
potassium, calcium, magnesium and sodium in grains and 
other foods. Also, the presence of tyramine in various 
cheeses and chicken livers as well as fatty acids and 
lipids in meats. 
2. Foods of Marine Origin 
Neurotoxins have been found in species of poisonous fish 
and paralytic toxins in polluted shellfish. Pesticide 
and heavy metal residues also have been detected in 
several species of edible fish. 
3. Food Additives and Contaminants 
Increasing quantities of intended food additives such as 
preservatives, antioxidants, sequestrants, surface-active 
agents, stabilizers and thickeners, bleaching and matur-
ing agents, buffers, acidulants, food colors, non-
nutritive and special dietary sweeteners, flavors and so 
forth are used in food processing technology to enhance 
the taste, structure or storage life of food. Examples 
of naturally occurring contaminants are the potent 
mycotoxins and bacterial toxins which result from fungal 
or bacterial contamination of foods. Man-made contam-
inants include antibiotics, pesticides, radionuclides, 
metals and processing degradation products. 
4. Water, Soft Drinks and Alcoholic Beverages 
These dietary constituents may contain various metals, 
xanthines, histamines, alcohol and congeners (p. 89). 
The absorption of drugs and foods is not similar. The absorption 
of the majority of drugs is dependent on lipid solubility, pH of the 
medium, particle size, physical form, and rate of dissociation. The 
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more l:i,pid-soluble the drtig, th~_ greater-.the e:Kte·ncbf absorption. Most 
drugs transported across the gastric or intestinal mucosa are transported 
by passive non-ionic diffusion. Active transport is believed to be X 
present with the digitalis glycosides and the pyrimidine compounds. Weak 
acids are usually absorbed in the stomach (pKa less than 2) and weak" 
bases (pKa less than 8) are usually absorbed in the upper part of the 
intestine. It is believed that digestive enzymes are not factors in 
drug absorption (16). 
Absorption of food depends on gastrointestinal secretions, pH and 
enzyme activity. Lipid solubility is only important in lipid absorption. 
Transport of food is not limited to passive diffusion (16). 
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Most drugs that interfere with nutrients and impair absorption are 
given for long-term treatment. An exception to this is the anti-
infective agents (16). 
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Drugs can increase vitamin excretion, interfere with absorption of 
vitamins or with vitamin utilization. This can occur even when the 
diet is adequate under normal circumstances. Drugs produce deficiency 
when compounds are chemically and functionally related to a vitamin, or 
they may be unrelated in structure and have a common side effect such as 
malabsorption (18). 
According to Roe (19), it can be generalized that with the exception 
of certain vitamin antagonists, drugs in therapeutic dosage interfere to 
a limited extent with nutrient utilization, having least effect over ~ 
short periods of time or where the intake of a nutrient exceeds demand. 
A person who is a chronic drug user may have the most effect. The drugs 
will emphasize a condition where nutrients are lacking either because of 
the disease condition or by marginal intakes of nutrients. 
Malabsorption of nutrients can occur because of drug intake. Abuse 
of cathartics can result in severe malabsorption problems. Malabsorption 
can occur through a number of mechanisms. A drug may provide a solution 
for nutrients such as in the case of mineral oil and interfere with x 
absorption of fat soluble vitamins. Cathartics may greatly induce 
intestinal transit time and cause the nutrients to pass too rapidly 
through the small intestine for optimal absorption (19). 
Some drugs may bind bile salts and impair absorption of fats and ' 
fat soluble vitamins. Some evidence exists that absorption of vitamin 
B12 may be decreased when a drug binds bile salts (19). 
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Some drugs cause cellular damage in the small intestine. This may 
be interference with the mitotic activity of the intestinal epithelium 
or destruction of the villous epithelium. If the microvilli are~ 
destroyed, there may be a loss or inhibition of intestinal enzymes 
(disaccharidases and peptidases) located along the brush border. Certain 
drugs may depress nutrient uptake from the small intestine. A drug may 
have a particular affinity for a nutrient. Roe (19) has prepared the 
following table (Table VI) of primary intestinal absorptive defects 
induced by drugs. 
Drugs can cause secondary malabsorption by affecting nutrient 
metabolism so the active transport system is inhibited. Examples that 
have been documented are related particularly to vitamin D and calcium 
transport (19). 
Drugs differ greatly in their chemical structure which have an 4 
effect on carbohydrate absorption. Because carbohydrate digestion and 
absorption are extremely efficient, mild malnutrition or a single drug 
used in a patient is probably insufficient to produce clinical signs 
of malabsorption. One group at risk is the elderly patient who may be 
poorly nourished and also taking several medications at the same time.~ 
The drugs may interact to produce malabsorption and further increase 
the malnourished state (20). 
Drug-Vitamin Interactions 
Some compounds act as antivitamins. Synthesis of antivitamins has 
either been on purpose or by chance. Metabolites that participate in 
enzyme reactions can be antagonized by a compound having a similar 
structure, chemically or physically. It must be similar enough that the 
Drug 
Mineral oil 
Phenolphthalein 
Neomycin 
Cholestyramine 
Potassium 
chloride 
Colchicine 
TABLE VI 
PRIMARY INTESTINAL ABSORPTIVE DEFECTS INDUCED BY DRUGS 
Usage 
Laxative 
Laxative 
Antibiotic to 
"sterilize" 
Hypocholesterolemic 
agent 
Bile acid sequestrant 
Potassium 
Anti-inflammatory 
agent in gout 
Malabsorption 
or Fecal 
Nutrient Loss 
Carotene, Vit. A, 
D, K 
Vitamin D, Ca 
Fat, nitrogen, Na, K, 
Ca, Fe, lactose, 
sucrose, vit. B12 
Fat, vit. A, K, B12 , D, 
Fe 
Vitamin B12 
Fat, carotene, Na, K, 
vit. B12 , lactose 
Mechanism 
Physical barrier 
Nutrients dissolve in mineral 
oil and are lost 
Micelle formation 
Intestinal hurry 
K depletion 
Loss of structural integrity 
Structural defect 
Pancreatic lipase 
Binding of bile acids (salts) 
Binding of bile acids (salts) and 
nutrients (e.g., Fe) 
Ideal pH 
Mitotic arrest 
Structural defect 
Enzyme damage 
Drug 
Biguanides: 
Metforrnin 
Phenf ormin 
Para-amino 
salicylic acid 
Salicylazo-
sulfapyridine 
(Azulf idine) 
Usage 
Hypoglycemic agents 
in diabetes) 
Anti-tuberculosis 
agent 
Anti-inflammatory 
agent in ulcerative 
colitis, and 
regional enteritis 
TABLE VI (Continued) 
Malabsorption 
or Fecal 
Nutrient Loss 
Vitamin B12 
Fat, folate, vitamin 
Bl2 
Folate 
Source: Daphne A. Roe, Drug Induced Nutritional Deficiencies (1976). 
Mechanism 
Competitive inhibition of B12 
absorption 
Mucosal block in B12 uptake 
Mucosal block in f olate uptake 
enzyme is deceived into taking the foreign molecule in place of the 
substrate (19). 
Substances which are folic acid antagonists are the following: 
1. Methotrexate--used in the treatment of malignant and benign 
diseases. 
2. Pyrimethaime--used in the treatment of chloroquine resistant 
malaria and ocular toxoplasmosis. 
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3. Pentamidine--used in the treatment of African trypanosomiasis. 
4. Triamterene--diuretic. 
5. Trimethoprim--potentiator of sulfonamides in the therapy of 
bacterial infection. 
Roe (19) shows the chemical structure and site of action of folate 
antagonists in Figure 4. 
The symptoms of folate deficiency due to drugs are weight loss,f 
megoblastic anemia, glossities, diarrhea. Ankle edema, hyperpigmenta-
tion of the skin, splenomegaly, and hepatomegaly may also be seen (19). 
In the body, there are vitamin B6 dependent reactions which are of 
concern when discussing the effects of drugs. Vitamin B6 is important ~ 
to the metabolism of tryptophan and its conversion to niacin. Roe (19) 
shows the importance of B6 in the body in the following diagram and 
the step which is blocked by B6 antagonists (Figure 5). 
It is obvious why drugs which are vitamin B6 antagonists are able 
to produce niacin deficiency (19). 
Vitamin B6 is important for the synthesis of several neuro- ~ 
transmitters and neurohormones. Roe (19) has shown the following rela-
tionships (Figure 6). These compounds are necessary for neuronal 
function at many levels. This explains the fact that there are 
N N 
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Source: Roe, Drug Induced Nutritional 
Deficiencies (1976). 
Figure 4. Structures and Site of Action 
of Folate Antagonists 
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neurological symptoms associated with vitamin B6 deficiency associated 
with drug uptake. 
Vitamin s12 may also be affected by certain drugs. The vitamin is 
protein bound as it occurs in animal products. The pepsin in the 
stomach and the acid pH split off vitamin s12 from its protein binding 
sites. The stomach acid enhances the binding of B12 to the gastric ~ 
intrinsic factor. Absorption of vitamin B12 is dependent on calcium. 
Vitamin B12 functions as a coenzyme (19). 
There is data to suggest that vitamin B12 is a necessary require-
ment for the cell uptake of the coenzyme form of folate. Figure 7 
shows sites of drug interactions. 
Tryptophon 
i 
/ 
Kynurenine ., Kynurenic acid 
Bs·P04 
Acetyl kynurenine i 
3- Hydroxykynurenine Xonthurenic acid 
B6P04 
BsP04 =f "'""""'"o" 
3- Hydroxyanthronilic acid 
l. N1oc1n 
Source: Roe, Drug Induced Nutritional Deficiencies 
(1976). 
Figure 5. Endogeneous Pathway for Niacin 
Biosynthesis From Tryptophan 
Showing Vitamin B6-Dependent 
Reactions and Step Preferen-
tially Blocked by B6 
Antagonists 
\ 
DRUG-INDUCED NUTRITIONAL DEFICIENCIES 
Glutamic acid d1!<:arboxylase 
1~ Glutarnic acid ---- -~ y Aminobutytic acid 
Pyridoxal - phosphate 
8,,-ar-® 
o, -co. 
2. Tryptophan ____. 5 Hydroxytryptophan _. 5-0H Tryptarrnrw 
Hydroxylase EJ., al (P) (serotonin) 
0 " -co? 
3. Tyrosine DOPA •Dopamine ::==-io 7 
Hydroxylase B,,-al- ® Hydroxylase .,L. 
Norepinephrine 1 CH3 
Epinephrine 
·Convulsions in drug induced 86 deficiency may be associated with 
decreased function of 8(, dependent. glutamic acid decarboxylase 
Source: Roe, Drug Induced Nutritional Deficiencies 
(1976). 
Figure 6. Vitamin B6 and the Synthesis of 
Neurotransmitters 
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Figure 7. Absorption of Vitamin B12 
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'f Metabolic interactions are present between vitamin B12 and folate. 
If methyltetrahydrofolate is to be converted to other folate coenzymes, 
the vitamin B12 dependent methyltransferase reaction must be present. 
When there is a deficiency of vitamin B12 the activity of the necessary 
enzyme is decreased. The result is lowered tissue levels of certain 
folate enzymes. These enzymes are necessary for purine and pyrimidine 
biosynthesis and, therefore, normal DNA biosynthesis. In both cases of 
folate and vitamin B12 deficiency, abnormal DNA synthesis results in 
megoblastic cells which are unable to mature in a normal manner or enter 
mitosis. This results in a condition known as megoblastic anemia (19). 
The largest proportion of all nutritional deficiencies caused by 
drugs fall into the category of absorption or utilization of vitamin 
B6 , folate and vitamin B12 (19). 
Five major groups of drugs function either as vitamin B6 antag-
onists or increase the turnover of vitamin B6 in the body: 
1. Antituberculous drugs--isonicotinic acid hydrazide, 
cycloserine. 
2. Hydralazine--used in treatment of hypertension 
3. Penicillamine--a metal chelator. 
4. L-Dopa--treatment of Parkinson's disease. 
5. Oral contraceptives (19, pp. 15-16). 
Other major groups of drugs have been shown to affect folate, 
either by affecting absorption or acting as a folate antagonist or in-
creasing the loss of folate from the body: 
1. Cytotoxic agent--methotrexate. 
2. Anti-malarial--pyrimethamine. 
3. Anti-convulsants--diphenylhydantion, phenobarbital, 
primidone. 
4. Diuretic--triamterene. 
5. Oral contraceptives. 
6. Antituberculous drug--cycloserine. 
7. Anti-inflammatory drugs--aspirin, salicylaxosulfapyridine, 
pentamidine. 
8. Anti-infective--aromatic diamidine (19, p. 16). 
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Four major groups of drugs affect absorption of vitamin B12 : 
1. Biguanides--metformin and phenformin. 
2. Antituberculous drug--paramino-salicylic acid. 
3. Bile acid sequestrant--cholestyramine. 
4. Potassium chloride (19, p. 17). 
Alcohol affects all three vitamins because it causes a direct toxic 
effect on the gastrointestinal tract, on the liver and the hemopoietic 
system (19). Figure 8 shows a comparison of mechanisms for production 
of vitamin B6 , folate and vitamin B12 depletion by drugs. 
Niacin is a water-soluble vitamin. Tuberculosis patients on 
isonicotinic hydrazide have been reported to have a pellagra-like ill-
ness. The niacin deficiency may be secondaryto the pyridoxine deficiency 
caused by the drug. Pyridoxine is necessary in the conversion of 
tryptophan to niacin (18). 
The coenzymes NAD (nicotinamide adenine dinucleotide) and NADP 
(nicotinamide adenine dinucleotide phosphate) are involved with hydrogen 
transport. Many dehydrogenases require one or the other for activity. 
NAD and NADP are necessary for carbohydrate metabolism, in protein 
metabolism and in fat metabolism. Nicotinamide coenzymes are important 
for microsomal mixed function oxidations. NADPH is necessary for micro-
somal drug oxidation reactions (19). 
Niacin deficiency not only affects endogenous metabolic systems but 
may also impair drug metabolism because of inactivation of biotransforma-
tion systems (19). 
Riboflavin in food is mainly in the form of two coenzymes--FMN 
(Flavin mononucleotides) and FAD (Flavin adenine dinucleotide). Free 
riboflavin is present in breads and cereals when they are enriched with 
B vitamins and iron. When riboflavin and FMN ar3 absorbed from the 
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Figure 8. Comparison of Mechanisms for Production 
of Vitamin B6, Folate and Vitamin Biz 
Depletion by Drugs 
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intestines, a large part of the vitamin and coenzyme is bound to albumin. 
Protein binding sites for drugs may displace riboflavin (19). 
Boric acid forms a complex with the ribityl side chain of ribo-
flavin. Absorbed boric acid causes hyperexcretion of riboflavin, either 
as the borate complex or as the free vitamin (19). 
Riboflavin is converted in the liver to FAD and FMN. Conversion of 
riboflavin to FMN involves the enzyme flavokinase and ATP. FMN is con-
verted to FAD by the enzyme FAD pyrophosphorylase and ATP (19). 
Riboflavin deficiency was found in one study in 50 per cent of a 
group of hospitalized alcoholic patients. The deficiency of riboflavin 
may be due to deficient intake; to impaired coenzyme synthesis if the 
patient has cirrhosis or to defective absorption of the vitamin (19). 
Absorption of riboflavin is increased in the presence of food in 
the intestinal tract. Investigators who made this observation thought 
it might be due to a decrease in intestinal transit rate; thereby, 
leaving the vitamin longer in the area of the absorption sites (19). 
Hyperthyroidism or administering thyroxine decreases riboflavin 
absorption. Riboflavin absorption is increased in hypothyroidism (19). 
Findings suggest that long term drug intake which requires in-
creased activity of the drug metabolizing enzymes may increase ribo-
flavin requirements (19). 
Figure 9 shows Flavin absorption, transport, biotransformation and 
excretion in man. 
Thiamine is important in the enzyme catabolism of pyruvic acid. It 
also functions in the decarboxylation of alpha-ketoglutaric and other 
a-keto acids. The co-enzyme form of thiamine is thiamine pyrophosphate. 
Blood pyruvate levels and blood levels of a-ketoglutarate are elevated 
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in severe thaimine deficiency. Thiamine pyrophosphate is required for 
the enzyme transketolase which functions to catalyze the production of 
ribose from glucose. Ribose is necessary for nucleotide formation. A 
useful test to detect minor degrees of thiamine deficiency is a test for 
erythrocyte transketolase activity (19). 
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Figure 9. Flavin Absorption, Trans-
port, Biotransformation 
and Excretion in Man 
Thiamine deficiency in alcoholics may be due to impaired absorption, 
impaired function of the co-enzyme form of thiamine, or a deficient in-
take of thiamine in the diet (19). 
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Thiamine needs may be increased if a patient is receiving digitalis 
alkaloids. In patients with digitalis intoxication, increased serum 
pyruvate levels have been found (19). 
Vitamin C is important in the oxidation-reductions reactions in the 
body. It is also necessary for normal synthesis of collagen and elastin. 
Vitamin C may function in mixed function oxidase systems. The synthesis 
of vitamin C may be increased by drugs which stimulate drug-metabolizing 
enzymes. Drugs which may cause tissue desaturation of ascorbic acid 
are alcohol, anorectic agents, anticonvulsant drugs, tetracycline and 
aspirin. Aspirin is the most important drug shown to cause tissue 
depletion. It causes a reduction in platelet levels of ascorbic acid 
(19). 
The first changes in vitamin C deficiency are decreased urinary 
excretion and decreased plasma volumes. Clinical signs which develop 
are follicular hyperkeratosis of the backs of backs of the arms, valves 
of the legs, thigh and buttocks. Further clinical signs are bleeding 
and swollen gums, conjunctiva! hemorrhages, and perifollicular hemor-
rhages (19). 
Subclinical deficiency of vitamin C has been noted among drug 
addicts. There may be some detrimental effects to massive doses of 
vitamin C. A group of paraplegics taking large doses of vitamin C 
(1000 mg.) daily were shown to have low vitamin B12 levels in the blood. 
It has been suggested that large amounts of vitamin C should not be 
taken with meals since it may destroy vitamin B12 in food. A high in-
take may also effect the utilization of betacarotene (19). 
Vitamin D is necessary for calcium uptake from the intestine. 
Recent studies have shown that sterols within the vitamin D class 
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function similar to steroid hormones. A deficiency of vitamin D in 
children results in rickets and in adult osteomalacia. Normal adults 
who have exposure to sunlight are assumed to get enough vitamin D with-
out considering dietary sources. Adults who are screened from the sun 
require vitamin D in the diet. Intestinal absorption is enhanced by 
the presence of bile salts and dietary lipids (19). 
Many drugs have been shown to interfere with absorption and 
metabolism of vitamin D. The drugs are corticosteroids, diphosphonates, 
anticonvulsants, antacids, laxatives, and certain sedatives such as 
gluthethimide. Mineral oil and phenolphthalein used as laxatives have 
caused clinical signs of vitamin D deficiency in adults and children. 
Aluminum hydroxide, anticonvulsants, and gluthethimide also have caused 
development of rickets or osteomalacia (19). 
Drugs and other foreign compounds which induce the drug metabolizing 
microsomal enzymes in the liver cause an accelerated degradation of 
vitamin n3 and 25-HCC. Some of the drugs which cause increased activity 
of the drug metabolizing microsomal enzymes are sedatives, oral anti-
diabetic agents, muscle relaxants and anticonvulsants (19). 
Four drugs which have been shown to accelerate the degradation of 
25-HCC severe enough to cause rickets or osteomalacia are phenobarbital, 
primidone, gluthethimide and diphenylhydantoin. Diphosphonates have 
been shown to block production of 1,25-DHCC in the kidney and induce 
osteomalacia (19). 
The major occurrence of drug-induced deficiency of vitamin D is 
found within institutionalized groups of patients who are kept indoors 
and may not be getting adequate vitamin D in the diet while on anti-
convulsant drug therapy (19). 
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Osteornalacia is found in adults and has symptoms of pain localized 
to the back and thighs. It may also include the shoulder region or 
ribs. Deformities may occur of the long bones, pelvis and thorax. 
Osteomalacia may be suspected in drug using persons who have symptoms 
of bone pain, weakness of the proximal limb muscles and progressive 
difficulty in walking. Biochemical findings include elevated serum 
alkaline phosphatase and changes in calcium and phosphorus levels in the 
serum (19). 
Vitamin K is important for normal blood coagulation. The following 
clotting factors are vitamin K dependent: Stuart-Prower factor (x), 
Christmas factor (IX), proconvertin (VII), and prothrombin (II). A 
deficiency of vitamin K in man has not been produced by a vitamin K free 
diet. The assumption is that the human needs for vitamin K can be sup-
plied by the intestinal synthesis of vitamin K2 (19). 
A synthesized form of vitamin K3 is used therapeutically. The 
chemical structure of vitamin K3 is closely related to menaquinone. 
Vitamin K1 is found in green leafy vegetables such as spinach, kale, 
cabbage and collard greens. Vitamin K is found in large amounts in 
pork liver (19). 
Broad spectrum antibiotics can decrease vitamin K2 synthesis in the 
intestine. Mineral oil and the bile acid sequestrant, cholestyramine can 
decrease vitamin K absorption. . The coumarin anticoagulants can cause 
vitamin K deficiency. Aspirin and other salicylates can induce hypo-
prothrombinemia (19). 
Vitamin A occurs naturally as retinal (vitamin A1 alcohol), dehydro-
retinol (vitamin A2 alcohol) or aldehyde derivative of these forms. 
The most valuable precursor of vitamin A is B-carotent. A dietary 
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deficiency is most likely to occur when the diet is mainly cereal 
sources lacking carotene sources and milk, liver and fish (19). 
The presence of dietary fat is important for optimal absorption of 
vitamin A. Drugs can interfere with vitamin A absorption, mineral oil, 
neomycin, cholestyramine and alcohol. Neomycin inhibits pancreatic 
lipase, may inactivate bile salts and may cause mucosal damage. 
Cholestyramine interferes with vitamin A absorption by absorbing bile 
salts (19). 
Vitamin A is necessary for specific visual function. Night blind-
ness is an early sign of vitamin A deficiency. It is also necessary 
for stabilization of cellular and intracellular membranes, synthesis of 
normal steroid metabolites and synthesis of mucopolysaccharides (19). 
Two major functions of vitamin A which are retinal dependent are 
the visual cycle and spermatogenesis. The conversion of retinal to 
retinal occurs through an oxidative process requiring ADH (alcohol 
dehydrogenase) and NAD. Conversion of retinal to retinal can be im-
paired by competitive utilization of ADH. Ethanol has a high affinity 
for the enzyme alcohol dehydrogenase. Alcoholics may fail to convert 
retinal to retinal. This may provide a mechanism to explain a common 
cause of male sterility in chronic alcoholics. It also explains why 
alcoholics may become night blind. Other contributing factors to 
vitamin A deficiency in alcoholics may also include poor food intake 
of the vitamin and malabsorption of the vitamin (19). 
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Vitamin E is present in the diet in vegetable oils, nuts, eggs, 
liver, wheat germ oil and margarine. Tocopherols are considered as 
dietary vitamin E. Gamma-tocopherol is found in soybean oil. Alpha-
tocopherol is also present in the diet (19). 
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When fat absorption is affected, the absorption of a-cocopherol is 
also affected. Vitamin E functions as a lipid antioxidant, it prevents 
the production of toxic lipid peroxides in the tissues. Vitamin E has 
a highly specific function in many tissues. Activity of the selenium-
gluthathione peroxidase system is related to inhibition of lipid 
peroxides. Cell components are protected from the toxic effects of 
peroxide by selenium-gluthathione peroxidase which breaks lipid peroxides 
down to hydroxy fatty acids and stops a further breakdown of peroxides to 
free radicals which can then again initiate peroxidation. Vitamin E 
works with the selenium-gluthathione peroxidase system to provide a 
chain breaking effect against peroxide formation (19). 
Patients studied who were given the drug clof ibrate showed a reduc-
tion in serum lipids and serum vitamin E levels. When the drugs were 
withdrawn, vitamin E returned to pre-treatment levels. A coagulation 
defect has been reported with patients on warfarin who are also taking 
moderately high doses of vitamin E and clofibrate. It is suggested that 
vitamin E may interfere with vitamin K utilization. Studies with 
laboratory animals show a prolonged prothrombin time and a hemorrhagic 
condition with hypervitaminosis E. These effects can be reversed by 
administration of vitamin K (19). 
Levels of total tocopherol in the body are related to total lipid 
content of the serum and to levels of certain lipid fractions. Serum 
tocopherol levels are high if total serum lipids are high (19). 
Minerals 
Iron is present in meats and other animal proteins as heme iron. 
Iron added to cereals is usually reduced iron, but in some instances 
ferrous sulfate is used. Heme iron is absorbed better than other food 
sources. Ferrous iron sources are absorbed better than ferric salts 
50 
or ferric complexes. Absorption of non-heme iron in the intestine is 
improved in the presence of ascorbic acid, fructose, sorbitol, meats and 
certain organic acids (lactic, citric, pyruvic and succinic). Some 
amino acids enhance iron absorption. Phosphate and phytates depress 
iron absorption (19). 
Some drugs depress iron absorption in man and animals. Bicarbonate 
depresses absorption of iron in guinea pigs. This may be of importance 
to patients who take quantities of bicarbonate as an antacid. Roe (19) 
found that tetracycline caused an inhibition of protein synthesis in the 
intestine. It has been suggested that alterated protein synthesis is 
associated with impaired iron uptake. One investigator (19) showed that 
tetracycline depressed the intestinal mucosa uptake of radioiron in 
rats. 
Inorganic iron preparations have been shown to depress blood levels 
of some antibiotics such as doxycycline, methacycline, tetracycline and 
oxytetracycline. Roe (19) showed that cholestyramine binds both heme 
iron and inorganic iron in vitro and in rats the drug impairs the absorp-
tion of inorganic iron. He also found that there were decreased non-heme 
iron stores in rats on long term treatment with cholestyramine. 
Aspirin or other salicylates are considered to be a prominent cause 
of iron deficiency anemia. If the aspirin taken amounts to 1 to 3 gms 
per day, bleeding in the gastrointestinal tract occurs in about 70 per 
cent of normal subjects. In pre-existing gastrointestinal diseases 
such as alcoholic gastritis, esophageal varices or peptic ulcer, aspirin 
may cause gastric hemorrhage in some patients (19). 
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Once iron is absorbed from the gastrointestinal tract, it is trans-
ported bound to transferrin in the plasma. Estrogens or contraceptive 
steroids increase the levels of transferrin in the plasma. One study 
has shown that oral contraceptives increase iron absorption. It has been 
postulated that this may occur because of high iron transferrin con-
centrations (19). 
Isoniazid (INH), a vitamin B6 antagonist, may impair the uptake of 
iron and cause sideroblastic anemia (19). 
Zinc is found in the diet in animal protein foods. Women receiving 
contraceptive steroids have been shown to have lower zinc plasma levels. 
There have not been studies to show women are zinc deficient when taking 
contraceptives (19). 
Corticosteroids have an effect on zinc status by increasing zinc 
renal losses (19). 
Malabsorption of zinc occurs with persons having a high level of 
phytate in the diet--a diet consisting primarily of cereal grains such 
as in countries like Iran and Egypt (19). 
Zinc plays an important role in the body in several processes. It 
is important for certain enzymes necessary for cellular oxidative 
processes, for normal protein synthesis, in metabolism of vitamin A. 
Zinc deficiency creates some syndromes which are not well explained. 
Zinc deficiency is believed to be involved in gonadal immaturity, dwarf-
ism, and anemia, and is found in Iranian and Egyptian boys and girls on 
a high phytate diet. One investigator (19) has suggested growth retarda-
tion in malabsorption conditions such as cystic fibrosis may be due to 
zinc deficiency. 
Evidence of vitamin A deficiency in alcoholics may be related to 
an impaired activity of alcohol dehydrogenase due to zinc deficiency 
(19). 
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Magnesium excretion is increased with the use of some diuretics in-
cluding ammonium chloride, mercurial diuretics, chlorothiazide and 
hydrochlorothiazide, Roe (19) found that magnesium depletion caused an 
increased sensitivity to digoxin induced arythmias. 
4ow blood magnesium levels have been associated with malabsorption 
which may be drug induced (19). 
Magnesium is an important activator of ATPase, enzymes associated 
with ribosomal protein synthesis and coenzyme A (19). 
Chronic alcoholics develop hypomagnesemia due to poor diet and 
hyperexcretion of magnesium in the urine. Magnesium deficiency is 
characterized by seizures, tetany, muscle weakness, ataxia, tremors and 
behavioral disturbances (19). 
Appetite Suppression Due to Drugs 
Regulation of appetite is a complex process involving peripheral, 
neural, and metabolic components. Neural mechanisms include a "feeding 
center" in the lateral hypothalamus and a "satiety center" in the ventro-
medial hypothalamus. Catecholamines in the brain seem to serve as 
neurotransmitters in the regulation of appetite (21). 
Some drugs impair appetite due to their central nervous system ef-
fects. Digitalis, phenformin and amphetamines fall in this category. 
Some drugs have an anticholinesterase property. They cause dryness of 
the mouth and impair taste sensation. Drugs which fall in this group 
are anticholinergics, phenothiazine tranquilizers, tricyclic 
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antidepressants and all antihistamines. Some drugs have gastic ir-
ritative properties that cause anorexia and nausea. These include 
potassium salts and iron, salicylates, theophyllin and antibiotics such 
as tetracycline and erythromycin (22). 
Some illnesses alter taste sensitivity. Carson and Formican (20) 
reviewed the literature concerning altered taste due to disease-
medication relationships. They have compiled the following tables 
(Tables VII and VIII). 
Drug Problems in the Geriatric Patient 
Advancing age modifies the drug response in man because renal func-
tion is lessened and active and passive absorption may be impaired due 
to lessened acid production in the stomach (23) (25). Ward and Hannah 
(26) state that the aging process is only partially understood. However, 
certain conditions are commonly encountered in the elderly, such as 
cardiovascular disease, atherosclerosis, osteoporosis, and hormonal 
imbalances. When there is a decline in renal function, drug overdose 
is likely to occur. 
Nine drugs which can cause special problems for the elderly are: 
analgesics, antibiotics, anticoagulants, atropine, digitalis, diuretics, 
laxatives, sedatives and tranquilizers (26). Many of these are routinely 
used for the geriatric patient. 
Elderly patients with Parkinson's disease are often given the drug 
levodopa. Treatment of Parkinson's disease with levodopa was proposed 
when it was found the dopamine content in portions of the brain was 
lower than normal in patients with the disease (27). Levodopa rather 
than dopamine is given orally, since levodopa crosses the blood-brain 
Disorder 
Endocrine disorders 
Adrenal cortical insufficiency 
Turner's syndrome (chromatin 
negative gonadal dysgenesis) 
Pseudohypoparathyroidism 
Diabetes 
Other diseases 
Cancer 
Familial dysautonomia 
Aglycogenesia 
Renal failure 
Sjogren's syndrome 
Cystic fibrosis 
Direct nerve damage 
Tongue lesions 
Facial paralysis 
Trauma 
Gunshot wounds 
Head injuries 
Burns 
TABLE VII 
MEDICAL PROBLEMS AFFECTING TASTE SENSITIVITY 
Effect 
Increased detection sensitivity 
Decreased sour and bitter sensitivity 
Decreased sour and bitter sensitivity 
Decreased sweet sensitivity with high blood sugar 
Not correlated with high blood sugar 
Decreased sweet and salt sensitivity 
Altered bitter sensitivity 
Decreased sensitivity 
Inability to recognize sweet 
Decreased sweet, salt, and sour sensitivity 
Decreased sensitivity, especially for bitter, salt and sour 
Increased sensitivity 
Decreased detection of salt and sweet 
Decreased sensitivity 
Decreased sensitivity 
Decreased sensitivity 
Decreased sensitivity 
Reference 
22 
21 
22 
23,24 
25 
26-28 
26,27 
29 
30 
31 
32 
33 
34 
35 
36 
37 
37 
Source: J. S. Carson and A. Gormicane, Disease-Medication Relationship in Altered Taste Sensitivity, 
J. Am. Dietet. A. (1976). 
Drug 
Amphetamines 
Anesthetics 
Cocaine 
Eucaine 
Amydricaine 
Amylocaine 
Isococaine and tropacocaine 
Benzocaine 
Amethocaine 
Lignocaine 
Acetyl sulfosalicylic acid 
Clofibrate 
Dinitrophenol 
d-Penicillamine 
5-Fluorouracil 
Griseofulvin 
Insulin 
Lithium carbonate 
5-Mercaptopyridoxal 
Phenindione 
Phenytoin 
Oxyfedrine 
TABLE VIII 
EFFECTS OF MEDICATIONS ON TASTE SENSITIVITY 
Effect 
Decreased sweet sensitivity in some; differs with individuals 
Increased bitter sensitivity 
Decreased sensitivity, especially sweet and bitter 
Decreased bitter and sweet sensitivity 
Decreased bitter and sweet sensitivity 
With high intake, loss of salt detection, decreased bitter 
sensitivity 
Decreased sweet sensitivity 
Decreased sour sensitivity 
Increased bitter sensitivity; decreased sweet sensitivity 
Decreased salt and sweet sensitivity 
Decreased sensitivity 
Decreased sensitivity 
Loss of salt taste; general hypogeusia 
General decrease in sensitivity 
Some alterations in bitter and sour sensitivity; increased 
sweet sensitiivity 
Decreased sensitivity 
With prolonged use, decreased sweet and salt sensitivity 
Strange, unpleasant taste 
Altered taste 
Decreased sensitivity 
Decreased sensitivity 
Decreased sensitivity 
Reference 
38 
39 
38 
38 
38 
38 
38 
38 
38 
38 
40 
40 
38 
41 
28 
40 
40 
42 
9 
43 
44 
45 
Vl 
Vl 
Drug 
Anti-thyroid agents 
Methimazole 
Methylthiouracil 
TABLE VIII (Continued) 
Decreased sensitivity 
Decreased sensitivity 
Effect 
Source: Carson and Gormicane, J. Am. Dietet. A. (1976). 
Reference 
46 
47 
barrier more readily. Dopamine is formed in the presence of a decar-
boxylase enzyme by the decarboxylation of L-dopa. 
Vitamin B6 , pridoxine, has been shown to interfere with levodopa. 
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It is known that the decarboxylase enzyme is dependent upon pyridoxine 
for the conversion of L-dopa to dopamine (28). Pyridoxine in oral doses 
of 10 to 25 mg reverses the antiparkinson effects of levodopa, therefore, 
multivitamin preparations or foods fortified with pyridoxine should not 
be given to patients on L-dopa therapy (28) (29). Foods particularly 
high in pyridoxine such as beef liver, pork, beans, oatmeal, sweet 
potatoes, bacon, and pyridoxine fortified breakfast cereals should be 
avoided. Some investigators feel the pyridoxine available in the stand-
ard daily diet is not likely to interfere with L-dopa activity (29). 
Some drugs used in the treatment of depression block the activity 
of the enzyme monoamine oxidase in the body. Monoamine oxidase is pres-
ent in the liver and gastrointestinal tract of man and the enzyme is 
responsible for detoxifying tyramine and other pressor amines ingested in 
foods. Two drugs which are monoamine oxidase inhibitors are phenelzine 
and tranylcypromine. These drugs block the activity of the enzyme 
monoamine oxidase and allow tyramine to reach the circulation. The 
result may be a potentially fatal hypertensive crisis. The severity of 
the reaction is dependent upon the amount of tyramine or other pressor 
agents consumed. Six milligrams of tyramine may increase blood pressure 
and 25 mg may produce severe hypertension. Certain cheeses, chicken 
livers, herring and some wines are particularly high in tyramine (30) 
(31). 
Hall (24) suggests the following simple rules to observe in pre-
scribing drugs for the elderly: 
1. Know the pharmacological action of the drugs being used 
and in particular how it is metabolized and excreted. 
2. Use the lowest dose that is effective in the individual 
patient. 
3. Use the fewest drugs the patient needs. 
4. Do not use drugs to treat symptoms without first discover-
ing the cause of the symptoms. 
5. Do not withhold drugs on account of old age when drug 
therapy may improve the old person's quality of life. 
6. Do not use a drug if the symptoms it causes are worse than 
those it is supposed to relieve. 
7. Do not continue to use a drug if it is no longer necessary. 
It is wise to review repeat prescriptions quarterly in all 
elderly patients (p. 582). 
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CHAPTER III 
PROCEDURE 
This research was stimulated by an awareness of increasing reports 
in the literature of drug-nutrient interactions. The geriatric patient 
has been particularly susceptible to drug~nutrient interactions because 
of factors having to do with the total health care and long term 
institutionalization. Through dietary consultation for a number of 
years in long term care facilities, personal observations regarding the 
problems of the elderly patient has further stimulated this interest. 
Selection of Subjects 
Five administrators of nursing homes were contacted for permission 
to study charts and interview patients in each facility. Of the five 
facilities chosen, three were 100 bed facilities, one was a 50 bed 
facility, and one had a bed capacity of 60 patients. All facilities 
were located in Oklahoma City, Oklahoma. The particular facilities in 
this study were chosen because of a previous knowledge of the facility 
and acquaintance with the administrator, by which it was felt permission 
would be obtained to conduct this study among the patients. 
After discussion with a statistician at Oklahoma State University, 
it was decided to do a striated random sample of each wing in the 
particular facility being studied. This was due to the fact that one 
wing might contain bed patients who needed heavy nursing care, another 
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might contain patients who were up walking around and would require 
lighter nursing care. It was, therefore, felt a better sampling would 
be obtained by a straited random sample of each wing since the medical 
problems could differ. Three of the facilities had four wings and two 
facilities had three wings. 
The subjects were selected by placing all the numbers of the 
patient beds in one wing in a container. The numbers were then drawn 
out of the container at random. It was decided to study approximately 
half of the patients in each wing. In facilities A and B, the number 
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of patients studied would be approximately 50 each, or a total of 100 
patients for the two facilities. In facilities C, D and E, the number 
of patients studied would be approximately 35 each, or 100 bed patients 
for the three facilities. The goal of this study would be to study ap-
proximately 200 patients in the five nursing homes. The number of 
patients studied in each wing of a particular facility is shown in Table 
IX. A total of 206 patients was chosen for the study. 
Data Collection 
A form was developed to collect the data from the patients (Appendix 
A). It was pre-tested in one facility among approximately 15 patients 
and found to be suitable for collecting the desired information. In the 
first part of the form the following information was collected from the 
patient's chart: patient's name, admission date, sex, height, weight, 
physician's name, diagnosis, age, physical limitations, diet order, 
supplements, where meal taken, written records of food intake and lab 
work significant to study. The second part of the form included medica-
tions given, date ordered, dosage and times of administration. The last 
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part of the form was a questionnaire regarding the specific foods the 
patient ate. The data was collected by personal interview with the 
patient. Observation of the patient was also written during the inter-
view. 
TABLE IX 
NUMBER OF PATIENTS SELECTED IN EACH FACILITY 
Win 
Facility I II III IV Total 
Facility A 15 9 13 16 53 
(100 beds) 
Facility B 12 11 14 14 51 
(100 beds) 
Facility C 10 12 10 None 32 
(50 beds) 
Facility D 14 7 13 None 34 
(60 beds) 
Facility E 10 7 10 9 36 
(100 beds) 
Analysis of Data 
The first objective in analyzing the data was to categorize each 
drug listed on the patient's chart. The purpose of this table was to 
show all drugs which were prescribed by the physician for all patients 
in the study. The chart is shown in Appendix B. The American Hospital 
Formulary Service (32) and the Physician's Desk Reference (33) were used 
to place the drugs in the correct drug categories. 
The second objective was to look at each drug listed in the chart 
and prepare a second chart showing the drugs which are reported in the 
literature as having drug-nutrient interactions. This chart is shown 
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in Appendix C. The reference used to prepare the chart was the Handbook 
of Interactions of Selected Drugs With Nutritional Status in Man (34). 
The handbook format is based on the American Hospital Formulary Service. 
The third objective was to relate the interactions found for spe-
cific drugs to the individual patient. A chart was prepared showing 
each patient by number and the following information: age, time in 
facility, weight gain or loss in one year's time, diagnosis, diet, 
number of drugs prescribed and drugs prescribed which have a drug-
nutrient interaction reported in the literature. Data was collected for 
the study in June and July of 1976. In late May and early June of 1977, 
the weight of each\ patient studied was rechecked to note whether there 
had been change. The chart showing the information discussed above is 
shown in Appendix D. 
The final goal of the analysis of data was to compare related f ac-
tors such as patient's age, length of time on the drug and patient's 
eating habits, and to make recommendations for improvement in methods 
used for recording information in the patient's chart. Better methods 
of recording would benefit the patient because someone might become 
aware of a drug-nutrient interaction which would otherwise be missed. 
CHAPTER IV 
RESULTS AND DISCUSSION 
Data collected from approximately 200 patient charts in five nursing 
homes was studied. One of the major goals of the study was to determine 
if the medications prescribed for the nursing home patient included some 
of the medications that have been reported in the literature to have 
drug-nutrient interactions. The other major goal was to assess the nu-
tritional status of the patient by observing weight change during one 
year and by checking records of food intake of the patient to see if 
there was an obvious relationship between drugs having a drug-nutrient 
interaction and patient's food intake. 
Drugs Prescribed 
Each medication prescribed on the chart by a physician was recorded 
as written on the chart and placed in the proper drug category. Drug 
categories were determined by following the listings in the American 
Hospital Formulary Service (32) and the Physician's Desk Reference (33). 
The drugs prescribed by categories are shown in Table X. The highest 
number of medications prescribed were narcotic and non-narcotic analge-
sics. A total of 213 prescriptions for analgesics was prescribed for 
206 patients. The next highest group of drugs prescribed was laxatives, 
173 prescriptions for 206 patients. Some patients had more than one 
prescription for a laxative. A small number of patients had more than 
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TABLE X 
NUMBER OF DRUGS PRESCRIBED IN FIVE NURSING HOMES 
BY DRUG CATEGORIES IN RANK ORDER 
Facilities 
Drug Categories A B c j) E 
Total 11umber () i- all <lrugs 
prescr1 bed: 
Anal;',l'S i cs 
Non-rrnrcotic 48 51 45 27 22 
Narculic 5 1 9 3 2 
L;ix<1lives 63 38 28 19 25 
V llami 11 an<l Mineral 
Supplements 60 30 24 23 22 
Tr:inqui.lizers 
Major 14 22 7 11 ll 
Minor 9 9 8 11 7 
Vasudilators 36 19 14 13 15 
Sedatives (hypnotic) 15 16 16 6 10 
CardJotonics 12 17 8 12 12 
lhuretics 11 15 13 9 11 
An ti-l1ypertensive 3 6 10 8 15 
Antacids 8 7 8 3 4 
Autitussive 3 8 13 6 0 
Stool Softeners 7 6 10 2 1 
Ant lnauseants 6 5 6 2 1 
Antibacterials 5 6 2 4 1 
J\11t:f.histamines 6 1, J 1 2 
l'otassium Replacements 3 4 2 4 2 
Autibiotics 6 4 0 1 5 
llypoclycernia Agents 2 4 4 1 2 
J\11 tr diarrheal s 0 7 1 1 4 
1\11 ti arthritics 3 1 s 1 2 
Anti.depressants 1 8 0 0 2 
Thyroid 5 3 1 () 1 
J\ntiasthmatics 4 2 () 1 2 
J\ntit'onvulsants 4 0 1 1 3 
lnsul ln 0 2 1 4 2 
J\ndrocortical Steroid 2 4 1 2 0 
Hormonal 2 2 1 1 2 
Anti-Parkinsonism Drugs 1 J 2 0 1 
Anti-psychotic Drugs 0 2 1 2 2 
Analeptic 1 2 2 0 1 
Anti-arrhythmics 0 2 0 2 1 
Anticoagulants 1 2 2 0 0 
Uricosuric 0 2 1 0 1 
Anticholincrgic 1 1 1 0 0 
Antimalarials 1 1 () 0 0 
Dige;;tant Aid 2 0 0 0 0 
J\nti-hyperllpcmics 1 1 0 0 0 
Antiprurltic 0 1 0 0 1 
AnLi-inflammntory 0 0 1 0 0 
Oral Contraceptives 1 () 0 0 0 
Appetite Suppressant 1 0 0 0 0 
J\ntineoplastics 0 0 1 0 0 
Spirits of Ferrnenti 0 0 0 0 1 
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Total 
1299 
213 
173 
159 
109 
97 
63 
61 
59 
42 
30 
30 
26 
20 
19 
16 
15 
14 
13 
13 
12 
11 
10 
9 
9 
9 
9 
8 
7 
7 
6 
5 
5 
4 
3 
2 
2 
2 
2 
1 
1 
1 
1 
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one type of analgesic prescribed. Vitamin and mineral supplements 
accounted for 159 prescriptions. Major and minor tranquilizers totaled 
109; vasodilators, 97 prescriptions; and sedatives, cardiotonics and 
diuretics, approximately 60 prescriptions in each category. The total 
number of drugs prescribed for 206 patients was 1,299. This was 
calculated to be an average of 6.4 prescriptions per patient in the 
study. The actual number of drugs prescribed per patient is shown in 
Table XI. Twenty-nine patients had four drug prescriptions, 20 patients 
had six drug prescriptions, 19 patients had seven drug prescriptions, 
and 18 patients had eight drug prescriptions. The highest number of 
drugs prescribed to one patient was 22. The next highest number of drugs 
prescribed to one patient was 17. The majority of patients were in the 
range of three to eight drug prescriptions. Eight patients were pre-
scribed two drugs, six were prescribed one drug and only one patient did 
not have any drugs ordered. Table IX shows the average patient in the 
nursing home is taking a large number of drugs. A complete listing of 
all drugs prescribed is shown in Appendix B. The number of drugs pre-
scribed to each patient in the study is shown in Appendix D. 
Many of the drug orders in the nursing homes studied were PRN (see 
abbreviations) orders. PRN orders in the facilities may have been given 
only rarely or they may have been a regular daily medication. Studying 
the PRN orders in detail would be another whole study. The number of 
PRN orders per patient ranged from one to ten. The average number of 
PRN orders was between two and six drugs. PRN orders are listed in 
parentheses for each patient in Appendix D. 
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TABLE IX 
RANGE IN THE NUMBER OF DRUGS PRESCRIBED PER PATIENT 
Number of Drugs Facility 
per Patient A B c D E Total 
0 0 0 0 1 0 1 
1 3 1 0 1 1 6 
2 2 3 1 2 0 8 
3 3 4 2 7 1 17 
4 11 3 3 5 7 29 
5 5 7 4 4 6 26 
6 6 7 2 5 1 21 
7 5 5 4 1 4 19 
8 5 5 3 3 2 18 
9 5 0 3 2 1 11 
10 2 0 1 2 2 7 
11 2 2 2 1 2 9 
12 3 3 2 0 0 8 
13 2 3 3 1 0 9 
17 0 1 0 0 0 1 
22 0 0 1 0 0 1 
Drugs With Reported Drug-Nutrient 
Interactions 
The next step in the study was to see if a drug-nutrient interac-
tion had been reported for that particular drug in the Handbook of 
Interactions of Selected Drugs With Nutritional Status in Man (34). 
Since this particular handbook is categorized with the same format as 
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the American Hospital Formulary Service (32), it is not difficult to find 
the generic name of the drug. Accuracy in evaluation is possible, even 
though the drug name may not be familiar. The drugs which have a re-
ported drug-nutrient interaction are shown in Appendix C. Each drug on 
the chart found to have a drug-nutrient interaction in the study is 
listed by drug category, trade name or generic name as listed on the 
patient's chart, and by the generic name and the number as shown in the 
American Hospital Formulary Service (32) and the Handbook of Interactions 
of Selected Drugs With Nutritional Status in Man (34). 
Two drug categories which were shown to have drug-nutrient interac-
tions are analgesics and laxatives. Both of these drug categories are 
prescribed to a large degree to the elderly patient. Other categories 
of drugs prescribed which have interactions were antacids, tranquilizers, 
antipsychotic drugs, sedatives, antidepressant drugs, diuretics, potas-
sium supplements, antihypertensive drugs, cardiotonics, anticonvulsant 
drugs, anticoagulant drugs, antineoplastic drugs, vasodilators, anti-
histaminics, antiasthmatic drugs, antilipemia agents, anti-arthritic, 
uricosuric drugs, hormonal drugs, andrenocortical steroids, anti-
parkinsonism drugs, antibiotics, antibacterials, analeptic drugs and 
J1ypoglycemla agents. 
Levodopa and drugs which are monoamine oxidase inhibitors were 
found to be prescribed for a small number of patients. Only one drug 
order was for a monoamine oxidase inhibitor and only three drug orders 
were for levodopa. In each instance, there was no indication in the 
diet order of possible interaction with certain foods. 
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Vitamin and mineral supplements were sometimes prescribed in large 
doses. Examples were vitamin C, 250 mg, 500 mg, 600 mg, or 750 mg per 
day; vitamin D, 50,000 I.U. per day, iron, 325 to 500 mg per day. In 
the review of literature, interactions with other nutrients when exces-
sively large amounts of certain vitamins are ingested was discussed. 
The RDA (36) (see abbreviations) for vitamin C is 45 mg per day, a drug 
order for 600 mg per day is 13 times the RDA. The RDA for vitamin D 
is 400 I.U. (see abbreviations) and the RDA for iron is 10 mg for older 
men and women. Large amounts of iron medication may cause nausea and 
diarrhea in some patients. 
Individual Patient Comparisons 
A table (Appendix D) was compiled which showed each individual 
patient and the drugs each received reported to have a drug-nutrient 
interaction. In order to make comparisons, the table also shows the 
age of the patient, the number of years in that particular facility, 
weight gain or loss in one year, the diagnosis of the patient, the diet 
preparation, the number of drugs ordered and the number of drugs on 
each patient which were PRN orders. The PRN orders are shown on the 
table in parentheses following the total number of drugs ordered. 
Almost every patient evaluated received at least one drug which had a 
reported drug-nutrient interaction. Many of the patients were receiving 
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two, three or more drugs which were shown to have an interaction. Some 
patients showed as high as six or seven of the drugs they were taking 
had reported interactions. 
Weight 
Comparisons of weight were made on each patient between June, 1976 
and June, 1977. The object was to note weight gain or loss within one 
year. It was not possible to obtain a weight for each patient in this 
study. Many of the charts were marked "unable to weight." In discussing 
this with the Directors of Nursing, each stated it was not possible to 
weigh bed patients or wheel chair patients. When weights were rechecked 
in June, 1977, two facilities had obtained methods to weigh bed and 
wheelchair patients. Facility C had purchased an instrument which looked 
like a flat piece of plywood to which two bathroom scales had been at-
tached on the underneath side. One scale was attached to each end of the 
piece of plywood. The piece of plywood was large enough to roll a wheel-
chair upon it. A reading was taken on each scale and the two figures 
were added together for the total. The weight of the wheelchair was then 
subtracted. The Director of Nursing in this facility maintained all bed 
patients could be weighe~ in a wheelchair. Weights were actually being 
done once a month for these patients and recorded. For this facility, 
weight changes are shown for three months for patients who were orig-
inally ''unable to weight." In facility B, scales had been purchased 
which could be attached to a patient lift. This, however, did not seem 
to be as convenient because it was still not being used on a regular 
basis. If a follow-up weight check was not possible because the patient 
had moved from the facility to another facility or had expired, it is 
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marked on the table with "M" or "Exp." Of the total number of patients 
studied, it was possible to obtain weights on 119 (or 58 per cent). Even 
though weight loss did appear on some patients (refer to Appendix D) who 
were taking drugs with a reported drug-nutrient interaction, it would be 
very difficult to make a statement as to cause and effect without lab 
work and without knowing something more about the food intake of the 
patient. 
Food Intake Records 
Food intake records were difficult to find. In an attempt to 
study food intake in relation to drug-nutrient interactions, a question-
naire was drawn up for a personal interview with the patient. In facil-
ity A, all 53 patients were visited. Much of the information obtained 
was questionable. The Director of Nursing was asked which patients 
could give reliable information. In each facility, when the list of 
patients was reviewed with the Director of Nursing, very few p8tients 
were considered able to give reliable information. Memory was a problem 
in trying to obtain reliable data even if the patient was oriented to the 
present. It was decided the only accurate food intake information would 
have to be obtained from the charts. This, too, proved to be disappoint-
ing. Food intakes were recorded as poor, fair, and good by the nursing 
staff, but recording on the chart was not done until sometime after the 
meal. Again, the information was questionable as to the memory of the 
aide or nurse charting on the nurses notes. Actual food intake records 
(by checking the patient's tray at mealtime) were kept in three facil-
ities. These were, however, kept on a sporadic basis. The food service 
supervisor stated she recorded the information if she had the time. She 
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also may have recorded only the meals while she was on duty. The record-
ing was usually by percentage of the total meal served. The patient ate 
100 per cent, 75 per cent, 50 per cent, etc. of the total amount served. 
While this did not identify which foods were eaten, it did tell something 
as to the amount. One of the excellent factors was the fact that in each 
facility, the food service supervisor was a HIEFSS (see abbreviations) 
member. The importance of a proper menu being served and the patient 
eating the food was well understood by the food service supervisor. 
Another positive factor was that each facility studied had a dietary 
consultant who was a registered dietitian. The m9nu in each facility 
was adequately written and portions served were correct in size to meet 
nutritional needs. In each case, the food service supervisor was very 
interested in the patient. The best information about how a patient was 
eating was verbal from the trained food service supervisor. She did 
observe, even though it was not recorded, and seemed to know who was eat-
ing well and who was not. In all five facilities studied, the available 
data in writing was so poor that it was not possible to calculate the 
exact nutrients received by the patient. 
Time of Administration of Drugs 
The relationship of time of administration of drugs to meals seemed 
important in view of the many drugs which show interactions such as 
anorexia, nausea, and vomiting. Drugs were not passed at the same time 
in all facilities. Table XII shows times of administration of drugs. 
Meal hours in facilities A, B, C and E were breakfast at 7:30 a.m., 
dinner, 12:00 noon, and supper at 5:30 p.m. In facility D, the five 
meal plan was used and the meal hours were 7:00 a.m., 10:00 a.m., 1:00 
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p.m., 4:00 p.m. and 7:00 p.m. In each facility, passing drugs involved 
a period of time--approximately one to one and one-half hours was 
necessary to pass all medications ordered. This meant that 8:00 a.m. 
medications were begun at 7:30 a.m. and finished at 8:30 or 9:00 a.m. 
The Directors of Nursing stated they sometimes received the medication 
before the meal, during the meal or after the meal. They stated they 
were not concerned with the meal hours in relation to medications unless 
it was stated on the label of the prescription by the pharmacist. In 
facility D, the meals were always before medication, no one received 
medication on an empty stomach unless so stated by the pharmacist. 
TABLE XII 
TIME OF ADMINISTRATION OF DRUGS 
Facility b.i.d. t. i.d. q.i.d. 
A 8-8 8-12-8 8-12-4-8 
B 8-8 8-12-8 8-12-4-8 
c 8-8 8-12-5 8-12-5-8 
D 8-8 8-12-4 8-12-4-8 
E 8-8 9-1-5 9-1-5-9 
Length of Time on Drug 
The length of time a patient was on a drug could only be evaluated 
by the date of the drug order on the chart. In most cases, little 
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change occurred in the drugs ordered or in dosages given from the time a 
patient was admitted to the facility. The exception was for antibiotics 
which were always given for short terms. If a patient was having side 
effects from a drug, the prescription was.reviewed by the pharmacist and 
the physician. 
Other Related Factors 
Of the 206 patients in the study, 65 were male (31.5 per cent) and 
141 (68.5 per cent) were female. All patients were Caucasian with the 
exception of one Negro patient. Each facility had a house physician 
which saw one-third to one-half of the patients in the facility. In 
facility A, 16 different physicians saw the 53 patients studied (House 
Physician 29); in facility B, 27 different physicians saw the 51 patients 
studied (House Physician 10); in facility C, 10 different physicians saw 
the 32 patients studied (House Physician 23); in facility D, four dif-
ferent physicians saw 32 patients studied (House Physician 29) and in 
facility E, 14 physicians saw the 36 patients studied (House Phsyician 
21). 
Many of the charts did not show the height of the patient; 32 charts 
(or 16 per cent) showed a record of the patient's height, 174 (or 85 
per cent) did not have a record of the patient's height. In discussing 
this with the Director of Nursing in each facility, it was stated they 
did not make an effort to get a patient's height upon admission. If the 
transfer sheet that came with the patient, or the physical examination 
which was completed by the physician, did not have a recorded height, it 
was not done. 
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The age of most patients in the study was between 75 and 100 years. 
Seventy per cent, or 145 patients, were in this age group. Table XIII 
shows the age of the patients in the study and the percentage in each 
age group. 
TABLE XIII 
NUMBER AND PER CENT OF PATIENTS IN STUDY BY AGE 
Patient Facility 
Age A B c D E Total % 
20-64 9 2 2 6 8 27 13.2 
65-69 3 3 2 3 2 13 6.4 
70-74 5 4 1 7 4 21 10.2 
75-79 3 5 5 9 4 26 12.6 
80-84 7 13 6 4 10 40 19.4 
85-89 12 12 10 5 4 43 20.8 
90+ 14 12 6 0 4 36 17.4 
Total 206 100.0 
The length of stay in a facility ranged from one year to 13 years. 
The average length of stay was from five tp six years. The time a 
patient was on a medication could be stuied only in relationship to the 
length of stay in the particular facility studied. The length of time 
each patient was in a particular facility is shown in Appendix D. It 
must be noted that facility E was a new facility which opened in June 
75 
of 1976 so it was not possible to record an accurate long-term length of 
stay in this facility. 
Laboratory data was limited for the patients studied in relation to 
identifying a drug-nutrient interaction. Lab work is ordered by the 
physician for the patient. Because long-term care facilities are not in-
tended for diagnostic centers but rather for care and treatment, lab work 
is usually ordered when a problem arises. Urine analysis may be ordered 
for a suspected bladder or kidney infection. Blood work may be ordered 
when it is important for treatment of the patient. It was often possible 
to find a hemoglobin and hematocrit on the chart included with blood 
work. But, very little was present in regard to nutrient levels in the 
blood. 
Medically defined conditions in the patients studied are shown in 
Table XIV. It was interesting to note that 76 patients had a diagnosis 
of Arteriosclerotic Heart Disease and 61 patients had a diagnosis of 
Arteriosclerosis. Many of the other diagnoses reported were related to 
these two conditions. Other conditions such as Parkinson's disease, 
osteomyelitis and rheumatoid arthritis were a small percentage of the 
total number of conditions. Diagnosis as listed on the chart for each 
patient studied is shown in Appendix D. 
The tables and discussion in this chapter present some of the fac-
tors which can play a part in a drug-nutrient interaction for a patient. 
TABLE XIV 
MEDICALLY DEFINED CONDITIONS IN FIVE NURSING 
HOMES IN RANK ORDER 
Facility 
Medically Defined Condition A B c D 
Arteriosclerotic heart disease 20 23 9 15 
Arteriosclerosis 24 10 10 5 
Organic brain syndrome 4 9 4 13 
Fractures 9 12 5 2 
Hypertension 4 3 4 8 
Cerebrovascular accident 10 5 4 2 
Arthritis 9 6 3 2 
Diabetes mellitus 3 6 4 4 
Osteoarthritis 9 3 0 4 
Mental retardation 6 0 1 2 
Congestive heart failure 1 1 2 4 
Cerebral arteriosclerosis 1 6 5 0 
Osteoporosis 7 1 1 4 
Chronic obstructive pulmonary disease 1 0 0 7 
Parkinson's disease 2 3 1 0 
Cancer 3 0 2 2 
Psychotic 3 1 1 0 
Schizophrenia 3 1 0 1 
Anemia 2 1 1 1 
Rheumatoid arthritis 1 1 0 2 
Cardiovasulcar insufficiency 3 0 0 1 
Osteomyelitis 0 1 1 1 
Total number of conditions 
76 
E Total 
9 76 
12 61 
10 40 
2 30 
9 28 
3 24 
3 23 
5 22 
4 20 
5 14 
5 13 
1 13 
0 13 
0 8 
1 7 
0 7 
1 6 
1 6 
0 5 
1 5 
0 4 
0 3 
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CHAPTER V 
SUMMARY AND RECOMMENDATIONS 
In this research an attempt was made to show some of the factors 
present with the older individual which may make him or her more at risk 
in the area of a drug-nutrient interaction. To identify a drug-nutrient 
interaction in the older individual is a challenge because the older 
individual generally already has many physical problems and the appear-
ance of the older individual may make it hard to spot change. The emo-
tional state is often poor if the individual is neglected by the family 
who may have placed him or her in the institution. To identify a drug-
nutrient interaction, the nurse, dietitian, pharmacist and the physician 
must be aware of physical changes in the older person. Two changes that 
should always be questioned are a dramatic weight change from normal and -\ 
a definite change in termperament from normal. 
It is important that correct heights and weights be kept on the 
charts for each patient. This study shows this is a weak area in the 
institutions. The importance of a height and weight is to provide some 
objective physical data by which to evaluate the patient. Taking a 
height is a one-time task and is not time consuming. A tape measure can 
be used if the person is unable to stand. Sometimes it is not always 
obvious by looking at someone whether or not there has been change. 
Often it goes unnoticed in the patient in which the change is gradual 
and the personnel seeing the individual daily are not aware the change 
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is occurring. 
This study shows that many institutionalized individuals are on a 
large number of drugs. While data is. available concerning mode of ac-
~ tion and safety of a single drug, comparable data is not available when 
a variety of drugs are given to the same patient. In a study conducted 
by the Department of Health, Education and Welfare on Physician's Drug 
Prescribing Patterns in Skilled Nursing Facilities (35) it was found 
an average of 6.1 drugs per patient were prescribed. The data for the 
study was drawn from a sample of 288 nursing homes and 3,458 patients 
across the United States. The range in number of prescriptions per 
patient was 0 to 23. This data closely parallels this study in which 
the average number of drugs prescribed was 6.4 per patient and the range 
in number of drugs was from 0 to 22 for the individual patient. The 
study completed by HEW and published in 1976 states: 
Patients in skilled nursing facilities tended to have more 
prescriptions for drugs that alleviate symptoms of illness 
than for drugs which might have a direct therapeutic action 
on the underlying causes of diseases (35, p. 7). 
One of the points covered in the review of literature is that the 
drug metabolizing enzymes are affected by lack of the correct nutrients 
in the body. This in turn affects how the body handles a particular 
drug or a group of drugs. The danger that is pointed out in the review 
of literature is in the individual who has many drugs prescribed for a 
long period of time and is not eating well in order to obtain the correct 
nutrients for the body's needs. It is sometimes thought that this can 
easily be remedied by simply taking a vitamin pill. A vitamin pill 
ordinarily contains at the most 10 nutrients and there are now 52 known 
nutrients found in food. Vitamin and mineral supplements in large doses 
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must be classified as drugs. It is the correct combination of foods 
that provide all the needed nutrients for the body. It is not difficult 
to meet the RDA for a nutrient with foods and a patient receiving the 
needed nutrients in the body is more nearly protected from a drug-
nutrient interaction. With the trained food service supervisor and the 
registered dietitian in the health facility, proper menu planning and 
portion size is present to provide the nutrients for the patient in the 
daily diet. It is, however, the amount of those nutrients that the 
patient actually takes into the body that is important rather than what 
is perfectly planned and served. When a meal is not eaten, no drastic 
change occurs to signal someone and only by keeping records at mealtime 
can it be known what is happening with the patient and his food intake. 
Recommendations from this study are: 
1. proper recording of heights and weights, 
2. charting of food intake on all patients, and 
3.. through further in-service education, an awareness be created 
of possible drug-nutrient interactions among all health care 
personnel. 
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QUESTIONNAIRE USED FOR COLLECTION OF DATA 
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INFORMATION FROM THE CHART 
Patient's Name Admission No. 
~~~~~~~~~~~~~~~~ 
Admission Date ~~~~~~ 
Physician's Name 
Sex ~--- Birthdate 
~~~~~~~~~~~~~~ 
Height __ _ 
Diagnosis from chart (physical and mental) 
85 
Weight 
Physical limitations (amputee, paralysis, wheelchair or bed patient) __ 
Diet order 
Supplements 
Where meals taken 
Record of food intake: 
Lab work significant to study: 
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Patient's Name 
Date Ordered Medication Dosage Time Administered 
Description of Patient (physical signs and symptoms--activity of patient) 
PATIENT INTERVIEW 
Name 
Food Intake: 
Milk: Do you drink milk? How much? 
Have you always drank milk? 
ice cream, etc.? 
Meat: Do you eat all meat served on trays? 
Do you have trouble chewing meat? 
Do you have trouble swallowing? 
Facility 
Do you eat cheese, 
Fruits and Vegetables: Do you like fruits and vegetables? 
Dislike: 
Do you drink orange juice daily? 
Can you eat fresh vegetables and fruit raw? 
Breads and Cereals: Do you eat cereal for breakfast? 
Kind: 
Do you eat bread? White or whole wheat 
------
Fluids: Do you drink water? How much? 
Snacks: Do you eat foods or fluids between meals? 
Does your family bring you food? 
What items? 
Does your food taste good to you? 
What is wrong with it? 
87 
What would be your chief complaint about the food served to you in this 
facility? 
APPENDIX B 
LISTING OF DRUGS IN USE 
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Facility 
A B c D E 
Vitamin and Mineral Supplements 
Vitamin C, 250 mg 1 0 0 1 0 
Vitamin C, 500 mg 3 1 1 0 1 
Albee with C 2 2 1 0 1 
Theragran M 4 3 0 4 4 
Theragran Liq 0 2 0 0 0 
Theragran Hematinic 2 0 0 0 1 
Stuarts Hematinic 1 0 0 0 0 
Ferrous Sulfate, 325 mg 4 1 1 3 2 
Feosol Spansules 0 0 0 1 1 
Fe Soy 0 1 0 0 0 
Ferro Grad 500 8 0 0 0 0 
Ferrolip 50 0 0 1 0 0 
Feosol Elixir 0 0 0 1 0 
Ferrous Cluconate 0 1 0 0 0 
Ferro Folic 0 1 0 0 0 
Ferg on 0 0 0 0 1 
Inf eron (Iron Inj.) 1 0 0 0 0 
Multiple Vitamin 7 4 2 3 0 
Deca Vi Sol 1 0 0 0 0 
Abdec Vitamins 1 0 0 0 0 
Surbex T 3 2 0 1 0 
Surbex 0 1 0 0 0 
Myadec 0 0 1 0 2 
Stress Tabs 4 0 0 0 2 
Riboflavin 1 0 0 0 0 
Li Vitamin Tabs 0 0 1 0 0 
Trinsicon 3 0 2 0 1 
Gevrabon 1 2 0 1 1 
Vitamin E, 100 I.U. 0 0 0 1 0 
Myade C 0 0 1 0 0 
Geritol 0 0 1 0 0 
Yeast Tabs 0 0 1 0 0 
Liquid Calcium 1 0 0 0 0 
Ca Gluconate 0 2 2 0 0 
Vi-Daylin 0 0 2 0 0 
Stress Caps 600 1 0 0 0 0 
Fol bison 1 0 0 0 0 
Poly-vi-sol 1 0 0 0 0 
Thera Combex 0 1 0 0 0 
Mi-Cebrin T 0 1 1 1 0 
Vitamin D, 50,000 I. u. 0 0 1 0 0 
Vitamin (kind not specified) 3 1 0 0 0 
One-a-Day Vitamin 0 1 0 0 0 
ViCon Forte 0 0 0 1 0 
Aquasol A 0 0 0 1 0 
DiCal D 0 0 0 1 0 
Geri flex 0 0 0 0 1 
Os cal 0 0 0 0 1 
Uni cap 0 0 2 0 0 
Nicotinic Acid 1 0 0 0 0 
Pyridoxine 0 0 0 0 1 
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Facility 
A B c D E 
Vitamin and Mineral Supplements (Continued) 
B-Complex 0 1 0 0 0 
B12 IM 5 2 2 2 0 
Nicobid 0 0 0 1 0 
Sodium Chloride Tabs 0 0 0 0 1 
Sodium Flouride 0 0 1 0 1 
Laxatives 
Nature's Remedy 1 0 0 0 0 
Solace Syrup 1 0 0 0 0 
Colace 4 0 1 3 1 
Pericolace Cap 0 4 0 0 0 
Laxative of Choice 9 12 6 1 13 
Ducolax Supp 4 2 1 1 1 
Ducolax Tabs 5 0 0 0 0 
Enema 7 0 1 0 0 
Fleet's Enema 1 4 0 1 0 
Dorbantyl Forte 0 0 0 2 1 
Milk of Magnesia 21 10 16 8 3 
Al op hen Tab 1 0 0 0 0 
Doxidan 2 0 1 0 1 
Dor bane 0 1 0 1 1 
Feen-a-Mint 0 0 0 0 1 
Anavac 2 0 0 0 1 
Cascara Sagrada 2 0 0 0 0 
Mineral Oil 1 1 0 1 0 
Modane 2 4 1 1 2 
Anti-Diarrheals 
Lomotil 0 6 1 1 3 
Kaopectate 0 1 0 0 1 
Stool Softeners 
Doxidan 0 1 3 0 0 
Surf ax 3 0 1 2 0 
Metamucil 2 0 2 0 1 
Dioctyl Sodium Sulfoc 0 0 1 0 0 
Dia lose 2 3 1 0 0 
Dialose Plus 0 1 1 0 0 
Milkinol 0 0 1 0 0 
Glysennid 0 1 0 0 0 
Analgesics (Non-narcotic) 
Aspirin 0 1 0 1 1 
Tylenol 22 16 3 10 7 
Anacin 0 1 0 1 1 
ASA 13 14 15 7 11 
ASA Supp 0 1 0 0 0 
Darvocet N 100 3 1 7 1 0 
Darvocet N 1 2 2 0 0 
Darvon and ASA 1 0 0 0 0 
Darvon 2 5 1 1 0 
Darvon Cmp 65 3 4 7 2 0 
Bufferin 2 2 3 0 0 
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Facility 
A B c D E 
Analgesics (Non-narcotic) (Continued) 
Pabalate 0 0 0 1 0 
Ascriptin (ASA with Maalox) 1 2 1 0 1 
Norgesic Tabs 0 0 2 0 0 
Phenaphen 0 0 1 1 1 
Equagesic 0 1 0 0 0 
Fiorinal 0 0 0 1 0 
Empirin 0 1 2 0 0 
Acetarnerophen Supp 0 0 1 0 0 
Riopan 0 0 0 1 0 
Analgesics (Narcotic) 
Mepergan Fortis 0 0 1 0 0 
Percodan 2 0 0 0 0 
Demerol 1 0 1 0 0 
Sparine 0 0 1 0 2 
Tylenol 112 2 0 0 3 0 
Tylenol 113 0 1 0 0 0 
Ernpirin 113 0 0 6 0 0 
Anticholinergic Agents 
Robinul 1 0 0 0 0 
Antacids 
Pepto-Bismol 0 1 0 0 0 
Gav is con (appetite suppressant) 1 1 0 1 0 
Mylan ta 0 1 1 0 0 
Mylicon 0 0 0 0 1 
Aldurox 0 0 1 0 0 
Maalox 3 2 1 0 0 
Gelusil 0 1 0 1 1 
Digel Liq 1 0 0 1 1 
Donnagel 0 0 1 0 0 
Donnatal 2 1 3 0 0 
Kolantal Gel 0 0 1 0 0 
Tums 0 0 0 0 1 
Respiratory and Cerebral Stimulants 
Metrazol 1 0 0 0 0 
Ritalin 0 0 0 0 1 
Tranquilizers (Minor) 
Librax 0 2 0 0 0 
Valium 6 3 3 3 6 
Equanil 0 1 0 1 0 
Librium 0 2 1 2 1 
Atarax 1 0 0 0 0 
Meprobamate 0 0 2 1 0 
Tranxene 1 0 0 1 0 
Vistaril 1 1 1 2 0 
Serentil 0 0 1 0 0 
Dantrium 0 0 0 1 0 
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Facility 
A B c D E 
Tranquilizers (Major) 
Mellaril 10 15 2 3 6 
Compazine 0 4 2 2 0 
Ilaldol 1 0 0 6 0 
Thorazine 3 3 3 0 5 
Anti-Psychotic 
Prolixin 0 0 0 0 1 
Na vane 0 0 0 2 0 
Stelazine 0 0 1 0 1 
Synalgos 0 1 0 0 0 
Lithium Carbonate 0 1 0 0 0 
Caffiene and Sodium Benzoate 0 1 0 0 0 
Sedatives (Hypnotic) 
Sominex 0 1 0 0 0 
Chloral Hydrate 3 5 2 1 2 
Seconal 0 1 0 0 0 
Dalmane 8 7 3 3 6 
Carbital 1 0 2 0 1 
Noctec 0 0 0 1 0 
Placidyl 0 0 2 0 0 
Phenobarbital 1 1 6 1 1 
Paraldehyde IM 1 0 0 0 0 
Nembutal 0 0 1 0 0 
Butisol Sodium 0 1 0 0 0 
Do rid en 1 0 0 0 0 
Anti-Depressants 
Aventyl 0 1 0 0 0 
Elavil 0 1 0 0 0 
Triavil 0 1 0 0 1 
Ser ax 0 1 0 0 0 
Tof ranil 1 3 0 0 1 
Caffiene and Sodium Benzoate 0 1 0 0 0 
Diuretics 
Thiomerin Inj. 0 1 0 0 0 
Las ix 6 8 8 6 6 
Hydrodiuril 0 2 0 3 1 
Diuril 2 1 0 0 0 
Dyazide 1 1 1 0 0 
Hydroten 1 0 0 0 0 
Aldactazide 0 2 1 0 2 
Diamox 0 0 1 0 1 
Esidrex 1 0 1 0 0 
Hydrochlorthiazyide 0 0 1 0 0 
Dyrenium (Triamterene) 0 1 0 0 1 
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Facility 
A B c D E 
Potassium Replacements 
Ko an 2 1 0 1 0 
Kaoclon 0 0 1 0 0 
K-Lyte 0 1 1 0 0 
Kl or-Vess 0 1 0 0 1 
Kaochlor Tabs 0 0 0 0 1 
Potassium Elixir 0 0 2 2 0 
Kol yum 1 0 0 0 0 
Potassium Chloride 0 1 0 1 0 
Anti-Hypertensive 
Hydropres 0 0 0 0 1 
Ser-ap-es 1 0 1 3 1 
Rauzide 0 0 0 0 1 
Aldomet 0 1 3 3 3 
Meta tens in 0 0 1 0 0 
Ismelin 0 1 0 0 1 
Salutensin 0 0 1 0 0 
Za:raxolyn 0 0 2 0 0 
Apresoline (diuretic) 0 0 0 1 1 
Diupress (diuretic) 1 0 2 0 0 
Aldoril 0 1 0 0 1 
Reserpine 0 0 0 0 2 
Naturetin 1 1 0 1 0 
Catapres 0 1 0 0 1 
Aldactone 0 1 0 0 1 
Eutron (MAO Inhibitor) 0 0 0 0 1 
Cardiotonics 
Digitoxin 1 1 1 0 1 
Lan ox in 9 10 4 7 6 
Crystodigin 1 1 1 1 2 
Dig ox in 0 4 2 4 2 
Purodigin 0 1 0 0 1 
Pers an tine 1 0 0 0 0 
Antiarrhythmics 
Quinidine Sulfate 0 0 0 0 1 
Inderol 0 2 0 2 0 
Anticonvulsants 
Dilan tin 3 0 1 1 2 
Mysoline 1 0 0 0 0 
Luminal Sodium 0 0 0 0 1 
Anticoagulants 
Coumadin 1 2 2 0 0 
Antineoplastics 
Cytoxan 0 0 1 0 0 
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Facility 
A B c D E 
Vasodilators 
Cyclospasmol 1 1 0 0 3 
Nitroglycerine 5 1 2 2 1 
Nitrobid 4 0 1 3 3 
Arlidin 0 1 1 0 0 
Pavabid 12 7 5 3 3 
Peritrate 0 1 0 0 0 
Hydergine 10 3 1 0 4 
Isordil 1 1 2 1 1 
Ethaquin 1 0 0 0 0 
Papaverine 0 0 0 1 0 
Quinam (used for leg cramps) 0 1 1 2 0 
Rob ax in 0 0 0 1 0 
Vasodilan 2 1 1 0 0 
Ceres pan 0 2 0 0 0 
Antihistaminics 
Triton 1 0 0 0 0 
Benadryl 1 1 2 1 0 
Benylin 1 2 0 0 0 
Con tac 1 0 0 0 0 
Ronical Timespan 0 0 1 0 0 
Oranade Span 1 0 0 0 0 
Dimetane 0 1 0 0 1 
Drixonal 1 0 0 0 0 
Disophrol 0 0 0 0 1 
Anticholinergic 
Cogent in 1 0 1 0 0 
Bentyl 0 l 0 0 0 
Anti-Malarial 
Quinine 1 1 0 0 0 
Antitussive (against cough) 
Tussiorganidan DM 0 1 0 0 0 
Ulo Syrup 0 1 0 0 0 
Vicks Formula 44 0 1 0 0 0 
Tussend (mild CNS depressant) 0 1 6 0 0 
Hycomine 0 0 1 0 0 
Ambelyn Exp 0 0 1 0 0 
Phenergan with Codeine 0 0 0 1 0 
Tessalon Pearl 0 0 0 1 0 
Robitussin 1 1 2 3 0 
Actified C 1 1 1 0 0 
Pherergan 1 2 1 1 0 
Ent ex 0 0 1 0 0 
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Facility 
A B c D E 
Anti-Asthmatic 
Elixophylin (diuretic, stimulant) 1 1 0 1 0 
Quibron 1 0 0 0 0 
Alupert 0 1 0 0 0 
Chlortrimeton 1 0 0 0 1 
Sudafed 0 0 0 0 1 
Brethine 1 0 0 0 0 
Anti-Inflammatory Anti-Arthritic 
Butazolidin 0 0 2 0 1 
Indocin 0 1 0 1 0 
Motrin 3 0 3 0 1 
Uricosuric (Blocks for matron of uric 
acid-gouty arthritis) 
Zyloprin 0 2 1 0 1 
Allopurinol 0 0 0 1 0 
Thyroid Hormone 
Synthroid 4 2 0 0 1 
Thyroid 1 1 1 0 0 
Hormonal 
Delatestyrl 1 0 0 0 0 
Depo-Provera 0 0 0 0 1 
Depo-Estradial 0 1 0 0 0 
Tace 1 0 0 0 0 
Deladumone Inj. 0 0 0 1 0 
Premarin 0 1 1 0 1 
Adrenocortical Steroid 
Durabolin 0 0 0 1 0 
Deca-Dnrabolin 1 1 0 1 0 
Prednisone 1 1 1 0 0 
Deltasone 0 1 0 0 0 
ATCH Decadron 0 1 0 0 0 
Anti-Parkinsonism 
L-Dopa 0 0 0 0 1 
Sinumet (contains L-Dopa) 0 0 1 0 0 
Do par 1 0 0 0 0 
Artane 0 2 1 0 0 
Kemadrin 0 1 0 0 0 
Antihyperlipemics 
Antromid-S 1 1 0 0 0 
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Facility 
A B c D E 
Antibiotics 
Ampicillin 0 0 0 0 2 
Tetracycline (Sumycin) 1 1 0 0 0 
Vibramycin 1 0 0 1 0 
Keflex 2 3 0 0 1 
Emycin Supp. 2 0 0 0 0 
Anti-Bacterial 
Gantanol 0 1 0 0 0 
Gantrisin 1 1 0 0 0 
Neg Gram 0 1 0 0 0 
Mandelamine 1 2 0 3 0 
Macrodantin 2 0 0 1 0 
Bactrin (urinary) 0 0 1 0 0 
Bacterium 0 1 1 0 0 
Septra Tabs 0 0 0 1 1 
Thiosulfil Forte 1 0 0 0 0 
Anti-Nauseant 
Dramamine 4 2 4 0 0 
Antivert 1 3 1 0 1 
Tigan Supp 0 0 0 2 0 
Bonine 1 0 0 0 0 
Wans Supp 0 0 1 0 0 
Appetite Suppressant 
Sanor ex (non-amphetamine) 1 0 0 0 0 
Digestant Aid 
Kuzyme 1 0 0 0 0 
Kanulase 1 0 0 0 0 
Analeptic 
Tofranil 1 2 1 0 1 
Tegretol 0 0 1 0 0 
Oral Contraceptives 
Ortho Novum 1 0 0 0 0 
Hypoglycemic Agents 
Tolinase 0 0 1 0 0 
Orinase 1 0 1 0 1 
Diabinese 1 1 2 1 1 
Dymelor 0 1 0 0 0 
DBI 0 2 0 0 0 
Insulin 
NPH 0 0 0 2 2 
Regular 0 1 1 0 0 
Lente 0 1 0 2 0 
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Facility 
A B c D E 
Spirits of Fermenti 
Whiskey 0 0 0 0 1 
Unclassified 
Derifil 2 0 0 0 0 
APPENDIX C 
LISTING OF DRUGS SHOWING DRUG-NUTRIENT 
INTERACTIONS 
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Drug Category 
Analgesics 
L;;xatives and 
Stonl Soften-
ers 
J\11Lcicids 
'l'ra11qui l i :~<·r 
Drugs as Listed 
on Chart 
Aspirin 
Anacin 
ASA 
Darvon & ASA 
Buffer in 
Pabalate 
Ascriptin 
Phenaphen 
Fiorinal 
Empirin 
Tylenol 
Darvocet N-100 
Acetaminophen 
Supplement 
Phenaphen 
Darvon 
Mepergan 
Percodan 
Demerol 
Colace 
Dialose 
Dorbantyl 
Pericolace 
Surf ax 
Doxidan 
Dioctyl Sodium 
Sulfoc 
Milkinol 
Ducolax 
Mineral Oil 
Milk of Magnesia 
Gelusil 
Thorazine 
Generic Name 
Salicylates 
28:08* 
Para-aminophenol 
.28:08 
Propoxyphene 
28:08 
Promethiazine 
28:24 
Oxycodone, 
Salicylate & 
Para-Aminophenol 
28:24 
Meperidine 
Para-Aminophenol 
28:24 
Diotyl Suffo-
succinate Salts 
56:12 
Bisacodyl 
56:12 
Petrolatum, i.Lqu eel 
56:12 
Magnesia ~1agma 
56: 04 
Aluminum llyd rox:id1• 
56:04 
Chlorpromazinc 
28:16.08 
Drug-Nutrient lnteracLions 
Dyspepsia, decrease absorption 
of tryptophan, possibly other 
cimino acids, glucose; decrease 
plasma, platelet, CJscorbic acid 
levels; decrense serum folate 
in patients with rheumatoid 
arthritis; increase urinary loss 
of ascorbic acid, aotassium, 
amino acids; antagonize Vit K 
heartburn in 7% patients on high 
doses 
May cause anorexia, nausea, 
vomiting, dyspepsia, diarrhea 
or constipation 
Can cause nausea, vomiting, con-
stipation, abdominal pain 
Anorexia, constipation, dry 
mouth, epigastric distress, 
nausea, vomiting 
Can decrease intestinal glucose 
absorption; causes intestinal 
hyper-peristalsis, rapid 
propulsion 
Decreiises absorption of carotene, 
Vit >.D,F,D, calcium, phosphate; 
can cause inrligestion, anorexia~ 
flatul enc,,; increases. intostina l 
motility; dissolves fat-soluble 
vit;imins 
Dl1 cr~':·1ses absorption of carotc11e, 
Vil. A. D, E, K, calcium, 
plio.c.;pllate; can cause indigcs-
t lo:1, anorexia, flatuJence; 
inc1~(•,1ses intl·stinal motility; 
di "solves fat-soluble' vitamins 
rn<1ct lvate Lh iamin<t>j thiamine un-
stAblo in basic pH; rlecrease 
Vil A absorption 
ln~l·ti.vate tl1iamine decrease 
Vit A absorption 
::;.in cause \·J<"ight g<:iin; can in-
crt· . is<· serum cholesterol 
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--------- ---------------------
Urug Catc•gory 
A11ti--l'sydwUc 
St•da L Lvcs 
Anli-
d0rressant,.; 
lJ i ul'.'et ics 
Drugs as Listed 
on Chart 
Syn<i logos 
Chloral Hydrate 
Phenobarbital 
Dor id en 
Aw•ntvl 
Elavil 
Triavil 
Tofranil 
Las Lx 
Generic Name 
Promethazine 
28:24 
Chloral Hydrate 
28:24 
Phenobarbital 
28:12 
Glutethimide 
28:24 
Nortriptyl ine 
28:16.04 
Amitriptyline 
28:16.04 
Nortripty line' 
Furosemide 
40:28 
Drug-Nutrient lnfnrn~tion 
Can c~use nnorl~x1n, constipa-
ticin, dry muutlt, c·pi:;astrlc 
clislress, nnu:--it'd, vomjtiug 
Decr<?ases serum levels of 
fola1 e, B12 1 pyridoxlnc, 25-
hvdroxy, Vlt D, calcium; 
decreases ;1bsorpLion of 
xy I n8e; dee reasL'S ert hrocyte 
fo\al c; incrcn.scs turnover of 
Vit IJ, VU K, c'~pr:cially in 
cld 1 cir en; Ci!ll decrease hone 
densi Ly, uiu-'t' osteomalacla 
May increCJsc Vit D turnover; 
may illtcr ,-alcium need; in-
~reBse hone resorption; can 
cau8P polyneuropathv 
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Can cause consl i_pation, nausea., 
vom·i t ·i ng, anorf~:xia., epigas t ric 
distn>ss, diarrhefl, peculiar 
taste, <JbJuminal cramps, black 
tongul:~, weight gain or loss 
Can cause nausea, ep Lgas tr ic-
di Rt ress, vomiting, anorexia, 
stomatitis, diarrhea, swelling 
of parotid glands, black tongue, 
const ipRtion, pcculi1r taste, 
dry 111outh, weight gnin 0r loss 
Can l·;1Uf-.C coo st Lpat ilJD, nause:1., 
vonrit ing, c111orexin, cp_i_g:istric: 
distress, dlarrheil, peculiar 
tastr:,. ;ih,lominal cr('1mps, b]<lck 
tongu,~, weight gaj n or loss 
The antidepressant drugs all 
affert the autonomic ncrvou3 
svst~m which are listed abnvP. 
May 1·au;;e nausea, vorni ting, 
dL1r«hea; nossibly c:nto'e 
pecul Lar sweet taste, oral and 
gastrLc burning sensati,m; in-
cre<!;.:;es excretion of calci.um, 
magn,'sium and potassitim; de-
crea~es serum crrlcjum Ln hyper-
Call~emia; decrt.:ascs '""~erum, 
mu~;cle magnesium~ incr1·ases 
se1·um zinc; decreases c·arbohy-
drate tolerancr; mDy be 
diabetogenic; f!cts on meduLlarv 
di l11t Lng segment nf kid1wy 
tubule 
Drug Category 
!Huret ics 
(Continued) 
Potassium 
Supplements 
Anti-
llypertensive 
Cardiotonics 
Drugs as Listed 
on Chart 
Diuril 
Hydrodiuril 
Dyazide 
Esidrex 
Al<lactazide 
Aldactone 
Diamox 
Koan 
Kaoclon 
K-Lyte 
Klor-vess 
Kaochlor tabs 
Potassium Elixir 
Kol yum 
Potassium Chloride 
Hydropres 
Diupress 
Aldomet 
Aldoril 
Se.r-ap-es 
Apresoline 
Eutron 
Digitoxin 
Lanoxin 
Crystodigin 
Dig ox in 
Purodigin 
Generic Name 
Thiazides 
40:28 
Spironolactone 
40:28 
Acetazolamide 
40:28 
Potassium 
Supplement 
40:12 
Reserpine 
24:08 
Methyldopa 
24:08 
Hydral az ine 
24:08 
Methylclothiazlde 
(not listed) 
Digitalis 
Glycosides 
24:04 
101 
Drug-Nutrient Interactions 
May cause anorexia, gastric 
irritation, nausea, vontLting, 
cramping, diarrhea; ·i.ncrease 
urinary excretiou of potassium, 
magnc·sium, zinc" riboflavin; 
decrease carbohydrate tolerance; 
um cause magnesium, potassium 
depiction; single dose increases 
calc.ium excretion; long-term use 
tends to decrease calcium 
excretion and increase serum 
calcium; may increase intestinal 
calc5um absorption or increase 
bone resorption 
IncrPases urinary calcium, 
magnesium 
Can cause Hnorex.la; increases 
urinary CAlcium, potassium 
Can decrease ahsorption of Vit 
Biz; slow release of potassium 
chloride; causes decrease of 
Ileal pH (acidification) 
Increases gastrointestinal 
mot i J i.ty d11d secretion; can 
cause nauS('a, vomiting, 
anorexia, dL1rrhea, weight gain 
Can cause drv mouth, gastro-
intestinal distention, con-
stipation or diarrhea 
Can cause a.nor('?:ia, nausea, 
vomitinv,, dia~rliea; can cause 
paresLhesias, peripheral 
neuritis, pyridoxlne depletion; 
forms hvdrazo1w wit II pyridoxine; 
inact i.vates tlw vitamin and 
increases its urinary excretion; 
may cl1elatc trace ml! ta ls 
MAO inhihitor--avoid tyramine 
containing .foods (see review 
of literature) 
Toxicity symptoms include 
anor£•xia, nausea, vomlting, 
diar1·hea; may cnmp~titively 
inbil' Lt glucose abscrption; 
may increase urinary magnesium, 
calc i.um 
Drug Category 
Anti-
convuJsants 
Anti-
coagulants 
Anti-
neoplastics 
Vasodilators 
Anti-
histaminics 
Anti-
asthmat ic 
Drugs as Listed 
on Chart 
Dilan tin 
Mysoline 
Luminal Sodium 
Coumadin 
Cytoxan 
Pavabid 
Papaverlne 
Cerespan 
Robaxin 
Dimetane 
Quibron 
Alupent 
Generic Name 
Phenvtoin 
28: 12 
Primidone 
28:12 
Phenobarbital 
Sodium 
Warfarin 
20:12.04 
Cyclophosphamide 
10:00 
Papaverine 
86:00 
Methocarhamol 
12:20 
Brompheniramine 
4:00 
Theophylline 
86:00 
Methocarbamol 
12:20 
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Drug-Nutrient Interactions 
Decrease scrum levels of folatc, 
Vit 812• oyridoxine, 25-hydroxy 
Vit D, calcium; decreases 
absorption of polyglutamic 
folic acid, calcium; decreases 
erythrocyte folate level; can 
decrease cerebrospinal fluid 
Vit B12 despite normal serum 
Vit Bl2• in absence of 
hematologic abnormalities, 
increases turnover of: Vit D, 
Vit K, especially in children; 
increases serum copper; can 
cause megoblastic anemia, 
polyneurGpathy; can decrease 
bone density; cause osteomalacia, 
osteoporosis 
Can cause anorexia, nausea, 
vomiting; can decrease serum 
levels of folic acid, Vit B12• 
pyridoxine; csn decrease 
absorption of calcium; can de-
crease erythrocyte folato; in-
creases turnover of Vit D, Vit 
K, especially in children; can 
decrease bone density; can 
cause osteomalacia 
(check Phenobarbital) 
Can cause nausea, vomiting, 
cramps, diarrhea, mouth ulcr· rs, 
competitive antagonism of Vit 
K and vice versa; drug effect 
may be antagonized by high 
doses of \'it E 
Catises anorexia, nausea, vomit-
ing, hemorrhagic colitis, oral 
mucos:il ulceration 
Can ,·,1use nausea, abdominal 
distr~ss, anorexia, constipa-
tion 
Can cause nausea 
Can cause nausea, vomiting, 
anorexia 
Can cause nausea, vomiting, 
epigastric or substernal pain 
Can cause nausea 
Drug Category 
Antilipemia 
Agents 
Anti-
in f lcimmatory 
Anti-
arthr it ic 
Uricosuric 
Hormonal 
Andrenocortical 
Steroid 
Drugs as Listed 
on Chart 
Antromid-S 
Butazolidin 
Indocin 
Zyloprin 
Premarin 
Ortho-Novum 
Prednisone 
Deltasone 
ACTH Decadron 
Generid Names 
Clof ibrate 
24:06 
Oxyphenbutazone 
Phenylbutazone 
Pyrazolone 
Deri'IIBtives 
28:08 
lndomethacin 
28:08 
Allopurinol 
92:00 
Estrog~nic 
substances 
conjugated 
68:12 
Corticosteroids 
68:04 
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Drug-Nutrient Interactions 
May cause nausea, loGse stools, 
dyspepsia, flatulence, vomit-
ing, stomatitis, gastritis; 
causes decreased taste acuity, 
unpleasant aftertaste; decreases 
absorption of glucose, xylose, 
iron, carotene, Vit Biz, 
electrolytes, medium-chain 
triglycerides 
Can cause ulcerative esophagitis, 
acute and reactivated gastric 
and duodenal ulcer, gastritis, 
epigastric pain, dyspepsia, 
nausea, vomiting, abdominal dis-
tention; can decrease absorption 
of tryptophan, possibly of other 
amino acids 
Decreases plasma and plate.let 
ascorbic acid levels; causes 
dyspepsia in 8Z of patients; 
may decrease absorption of 
amino acids, xylose 
Infrequently causes nausea, 
vomiting, diarrhea, inter-
mittant abdominal pain; may in-
crease liver storage of iron; 
decrease iron absorption; may 
inhibit conversion of mucosal 
ferritin to ferrous iron 
(transportable form) 
Can cause nausea, vomiting, 
gastrointestinal cramps, bloat-
ing; alter olasma amino acid 
pattern; alter tryptophan 
metabolism; decrease serum, 
leukocyte, platelet ascorbic 
acid levels; may decrease serum 
Vit B12 , folate, pyridoxine, 
riboflavin, magnesium, zinc, 
albumin; decrease serum calcium; 
increase erythrocyte zinc; in-
crease hemoglobin,hernatocrit; 
can cause polyneuropathy, 
peripheral neuritis, 
megaloblastic anemia; enhanced 
effects occur in patients on 
marginal diets 
Decrease absorption of calcium, 
phosphorus; increase urinary 
ascorbic acid, calcium, potas-
sium, zinc, nitrogen; decrease 
nitrogen balance; decrease serum 
zinc; increase blood glucose, 
(continued on next page) 
Drug Cate~ory 
Adrenocortical 
Steroid 
(Continued) 
Anti-
l'arkinson 
Antibiotl cs 
i\nti-
bacteri.al 
i\nall'ptic 
llypoglyc·emia 
Agents 
Drugs e's Listed 
on Chart 
L-Dopa 
Sinumet 
Dopar 
Ampi.cillin 
Tetracycline 
Macrodantin 
Bactrim 
Tofrani 1 
DBI 
Generic Name 
Levo dopa 
92:00 
Penicillins 
8:12.16 
Tetracyclines 
8:12.24 
Nitrofutantoin 
8:36 
Salicylazo-
sulfapyridine 
8:24 
Imipramine 
28:16.04 
Phenformi.n 
68:20 
•Drug-Nutrient lnteractions 
(Continued) 
serum triglycerides, serum 
cholesterol; increase need for 
fol.ate, Vit D, pyridoxine, 
Vit C; delay wound healing, 
promote gastrointestinal 
ulceration 
Antagonizes pyridoxine, 10-25 
mg pyridoxine decreases drug 
effectiveness; increased need 
for ascorbic acid, pyridoxine; 
decreases absorption of 
tryptophan and other amino 
acids; drug effect decreased 
by high protein diet; increases 
urinary sodium, p~tassium 
Can cause nausea, vomiting, 
diarrhea, hypokalemia, renal 
potassium wasting 
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'Can cause nausea, vomiting, 
diarrhea, anorexia, glossitis; 
decrease absorption of calcium, 
iron, magnesium, zinc, amino 
acids, fat, xylose; decrease 
synthesis of Vit K hy intestinal 
bacteria 
Frequently causes anorexia, 
nausea, vomiting, can cause 
megoblastic anemia; decreases 
serum folate 
May cause gastric distress, 
nausea, vomiting, anorexia; 
decreases serum fol.ate, s~·rum 
iron; antagonizes response to 
folate supplement 
Can cause nausea, vomiting, 
anorexia, diarrhea, epigastric 
distress, peculiar taste, 
stomatitis, abdominal cr:amps, 
black tongue 
Can cause unpleasant metallic 
taste, anorexia~ nausea; de-
creases rate of glucose absorp-
tion in human ileum; dose 
related effect decreases absorp-
tion of Vit s12 , fat, calcium, 
amino acids 
*Referencing number following the system reported in Interactions of Selected Drugs with 
Nutritional Status in Man. Am. Dietet. A. October, 1976. 
APPENDIX D 
COMPILED PATIENT INFORMATION 
105 
106 
Facility A 
Drugs with 
Patient Years in Weight No. of Reported 
No. Age Facility + or - Diagnosis Diet Drugs Interaction 
1 72 1 0 Cerebral AS, Fx rt leg, Reg 4 (2) l'avabid 
arterial occulusive MOM 
disease, limited _Tylenol 
alertness 
2 96 6 +2 Gen. AS, arthritis, Reg 5(4) /\SA 
osteoarthritis, Lax of Choice 
osteoporosis, 
senility 
3 79 6\ +8 AS, osteoporosis, Reg 6(2) Pavabi.d 
osteoarthritis MOM 
senile agitation ASA 
4 73 4 -9 ASHD, COPD, Fx Reg 9(6) Lax of Choice 
left leg & Darvon 65 
shoulder, OBS, Quibron 
history of GI bleeding, 
some disorientation 
5 86 2~ +4 ShinJ!les, ASHD, Low 7(5) Tofranil 
osteoarthritis, Res Ducolax 
CVI Tylenol 
Mineral Oil 
6 93 1 0 Senility Reg 4 (1) Lax of Choice 
7 88 2~ -3 ASHD, Fx third Reg 11(3) Pavabid 
vertebra Las ix 
Koan formula 
Dia lose 
Lax of Choice 
Tylenol 
8 77 1 -8 Parkinson's disease, Reg 6(1) Pavabid 
hypertenson, rt Dilan tin 
hemiparesis, Fx rt MOM 
leg, post CVA 
9 98 1!2 +14 ASHD, Gen AS, post Reg 8 (5) Pavabid 
FX rt hip, Lax of Choice 
osteoporosis, Tylenol 
osteoarthritis, 
anemia 
LO 71 1 M AS, cerebrovascular Reg 10 (3) Dilan tin 
accident, post open Surf ax 
heart surgery Darvocet N-100 
Do par 
Antromid s 
Macrodantin 
11 63 7 -49 Diabetes rrellitus, 1500 6(2) ASA 
obesity, AS, OBS cal llucolax 
ADA Thorazine 
12 87 4 -6 ASHD, blind, senile, Reg 5(4) ASA 
arthritis Las ix 
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Facility A (Continued) 
Drugs wjth 
Patient Years in Weight No. of Reported 
No. Age Facility + or - Diagnosis Diet Drugs lnteraction 
13 82 2 +JS Malnutrition, arthritis Reg 7 (3) ASA 
Rt. inguinal hernia, Las ix 
hiatus hernia, Lanoxin 
psoriasis 
14 71 2 -3 ASHD, diabetes, CVA, 1800 8(1) Pavabid 
Fx rt hip cal Tylenol 
ADA MOM 
Chloral hydrate 
15 87 9 +4 ASHD, AS, confused Reg 5(4) Ducolax 
deg. arthritis, Tylenol 
anemia Lax of Choice 
16 82 2~ Unable Cerebral thrombosis, Soft 6(4) AscriDtin 
post CVA Darvon Comp 65 
Chloral hydrate 
17 32 4 -7 Psychotic, MR, pre- 1200 9(1) Colace 
frontal lobotomy, cal MOM 
schizophrenia ADA Phenobarbital 
Thorazine 
18 82 2 Exp. Senile, AS, 1500 7(4) L111ox in 
hypertension, cal Bufferin 
arthritis ADA Dulcolax 
Esidrix 
19 80 l~ +2 Parkinson ism, OBD, Reg 8 (2) Lax of Choice 
CVI, ASHD, coronary Chloral hydrate 
and vascular disease 
:rn 87 4 Unable Senility, AS, Mech 1(0) ASA 
osteoarthritis soft 
21 38 1 -83 Post-op astrocytoma, Reg 14(8) Percodan 
Exp. CA brain & extension Dulcolax 
to thoracic spinal Colace 
cord Tylenol 
Darvon 
22 98 7 Unable Mental deterioration, Pur- 3(0) Lax of Choice 
AS, CV disease, eed Crystodigin 
osteoporosis 
23 90 3 Unable ASHD, OBS, CVD Reg l 2 (6) ASA 
Maalox 
Tylenol 
24 87 2~ Unable ASHD, deg. arthritis, Reg 4 (2) MOM 
CVA Tylenol 
25 94 Unable Senility, deg. Reg 7(2) Pavabid 
arthritis, AS MOM 
Las ix 
26 69 1 Unable ASHD, Ca prostate to Reg 12 (7) Darvocet N HJ() 
dorsal spine, Demerol 
osteoarthritis, Doxidan 
hypothyroidism MOM 
P<>rcodan 
Facility A (Continued) 
Pati"ut 
No. 
27 
28 
29 
30 
31 
32 
34 
35 
l6 
37 
Years in Weight 
Age F;1cility + or - Diagnosis 
89 4 Unable Confused, senile, 
87 2 
101 5 
87 7 
68 1 
92 5 
78 9 
74 1 
58 1 
87 7 
82 
91. 
Unable 
Unable 
Unable 
Exp. 
Fx left hip, 
osteoarthritis, 
osteoporosis 
Arthritis, AS, 
hypertension 
osteoarthritis 
Confused, ca of colon, 
stroke affecting rt 
side 
ASHD, Fx pelvis, 
hypertension 
Unable AS, stroke with left 
hemiplegia, 
osteoporosis, 
osteoarthritis 
Unable AS, CVI, senile 
Unable Senile psychosis, 
gen AS, osteo-
arthritis 
Unable ASHD, AS, senile 
Exp. psychosis 
Unable AS, post cva with 
Exp. spastic paralysis 
llni!ble 
M 
U11able 
Exp. 
+2 
and brain stem 
lesion, post MI, 
decubitus low back 
and hip 
AS, ASHD, blind, 
confused and dis-
oriented, 
osteoporosis 
Gen. AS, ASHD, post 
cva, some confusion 
Senile, agitated de-
pression, Fx rt hip 
Diet 
Pur-
eed 
Pur-
eed 
Pur-
eed 
Pur-
eed 
No. or 
Drugs 
11 (4) 
5(1) 
6(2} 
6 (2) 
Lo NR 6(2) 
2 gm 
Reg 
Gr. 
Pur-
eed 
Pur-
eed 
Pur-
eed 
Pur-
eed 
l'ur-
eed 
Reg 
7 ( 3) 
9(3) 
3(2) 
1(2) 
6(2) 
8 (3) 
7 (2) 
Drugs with 
Reported 
Interact ion 
Diuril 
Koan Liq 
MOM 
ASA 
Lanoxin 
Xaalox 
Darvon Cmp. 65 
Diuril 
Lax of Choice 
Macrodantin 
Surf ax 
Pavabid 
Ser-ap-es 
Darvocet N 
Lanoxin 
Diupress 
ASA 
Colace 
Tylenol 
Lanoxin 
Tylenol 
Dul co lax 
Lax of Choice 
Dialose 
Darvon 
Dulcolax 
ASA 
Tetracycline 
MOM 
Tvlenol 
Lanoxin 
Doxidan 
Colace 
Tylenol 
Dyazide 
Dilan tin 
Lanoxin 
Tylenol 
MOM 
Lanoxin 
Las ix 
Tylenol 
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Vaci.lily II (Continued) 
--------------------------------------------
l'c1 L .i ent 
No. 
39 
40 
41 
42 
43 
41+ 
45 
46 
47 
48 
49 
'.JO 
51 
52 
53 
Years in Weight 
/\ge Facility + or - Diagnosis 
90 1'2 Unable Confusion, ASHD, AS 
32 6 
57 9 
2'l 9 
63 9 
82 
62 J 
94 3 
74 6 
86 4~ 
93 4!:; 
89 9 
90 4 
22 4 
36 7 
-3 MR, congential hip 
deformity 
Unable Severe deforme<l 
rheumatoid 
arthritis 
0 
+l 
-22 
MR 
Reg. enteritis, 
chronic 
schlzvphrenia 
Post Fx rt hip, 
post CVA 
Unable Confused and dis-
oriented, /\S, 
cerebral Thrombosis 
with hemiplegia 
-9 ASHD, senility, 
confused 
-4 
-24 
Unable 
Exp. 
-3 
+5 
Unable 
+7 
Schizophrenia, 
paranoid, confused 
Diabetes mellitus, 
OBS, ASHD, CHF, 
prior MI 
Fx Femur, hostile, 
confused, arthritis, 
acute leukr:mia 
CVA, gen AS, alert, 
oriented, benign 
prostrate hypertrophy 
Gen AS, ASHD, chr. 
cholecystitis, 
osteoarthritis 
MR, CP, multiple 
birth defects, 
thrombophlebitis 
MR 
Diet 
Reg 
1000 
cal 
Reg 
1200 
cal 
Reg 
Reg 
Reg 
Reg 
Reg 
1400 
cal 
Reg 
Reg 
1200 
cal 
Reg 
1200 
cal 
Drugs wit.Ii 
No. of Reported 
Drugs Interact ion 
12(3) MOM 
4 (2) 
4(2) 
5(2) 
] 0(2) 
14(5) 
2(2) 
8(5) 
l(O) 
5(3) 
12 ()) 
1(1) 
9(6) 
4 (1) 
4(3) 
Pavabid 
Las ix 
Prednisonc 
Bufferin 
Tylenol 
MOM 
Tylenol 
MOM 
ASA 
Ortho Novum 
Ducolax 
Pavabi<l 
Thorazine 
Darvon ASA 
Maalox 
Kolyun 
MOM 
Lanoxin 
MOM 
Ty 1.enol 
ASA 
MOM 
Digitoxin 
MOM 
Tylenol 
MOM 
Darvocet N 100 
Tylenol 
MOM 
Surf ax 
Pavabid 
Tylenol 
Du col ax 
Tylenol 
Coumadin 
Mysoline 
ASA 
MOM 
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llO 
.1cillty II 
Drugs wit 11 
Pat i "11 t Years in \/eight No. of Rerorted 
No. Age Facility + or - Diagnosis Diet Drugs Interaction 
87 21, +5 AS, blind Reg 2 (I)) Non<' 
2 82 3 +4 ASllD 1600 5(2) Lax of Choi CL' 
cal Tylenol 
Chloral Hydrate 
3 79 5 Unable Cerebral As, CBS, Reg 5(2) MOM 
Exp. diabetes mellitus, DBI 
mod. confusion 
4 78 3 +13 Senile dementia Lo 11 (7) Dialose 
Res Darvocet N 
Aldactazide 
Digoxin 
MOM 
s 87 21; +17 AS, OBS, confused Reg 3 (2) Tylenol 
6 79 2 Unable Post !'!I, post CVA Reg 9(4) Pavabid 
Exp. MOM 
Lanoxin 
ASA 
K-Lyte 
Las ix 
7 93 2 Unable Cerebral AS, CBS, Reg 10 (2) ASA 
M cerebral thrombosis, Lanoxin 
confused Perico lace 
Ducolax 
8 % 21; -312 ASHD, post Fx rt hip, Reg 9(3) Thorazine 
osteoarthritis, Peri-Colace 
depressed Ascriptin 
ASA 
Digoxin 
9 73 1 Same Rheumatoid arthritis, Reg s (3) Darvon 
infected left hip Ascriptin 
with draining sinus 
10 68 3 -28 Schizophrenic reaction 1000 6(1) Chloral Hydrate 
cal Thorazine 
Tetracycline 
11 75 2 Same AS, aortic aneurysm Lo 3 (1) Pavabid 
below renal vessels Salt Tylenol 
vertigo Coumadin 
12 82 2~ Unable ASHD, diabetes mellitus Reg 8(4) MOM 
Exp. ASA 
Lanoxin 
Las ix 
Koan 
13 69 7 Same Spinal cord deteriora- Reg 7(4) ASA 
tion, spastic movement 
of lower extremities 
14 90 3 -3 ASHD, arthritis, Reg 5(3) Peri-co lace 
confused Lax of Choice 
Buff er in 
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Facility B (Continued) 
Drugs with 
Patient Years in Weight No. of Reported 
No. Age Facility + or - Diagnosis Diet Drugs Interaction 
15 84 2~ +5 Deg. joint disease, Lo 11 (5) Prednisone 
obesity, ASCVD Na Las ix 
Tylenol 
Lax of Choice 
16 63 2 Unable CBS, psoriasis, Reg 17(8) Dyazide 
M chr. alcoholism Peri-co lace 
Digoxin 
Maalox 
Phenobarbital 
17 84 2 Unable ASCVD, diabetes Reg 7 ( 5) Digitoxin 
M mellitus, gouty, Tylenol 
arthritis, Darvocet 
hypertension DBI 
18 87 2 +2 ASHD, hip Fx, post Lo 6(5) Empirin 
hip pinning Fat Lax of Choice 
Tylenol 
19 84 10 +l Diabetes mellitus, Lib. 8 (3) Crystodigin 
hypertension, Diab MOM 
osteornyelitis ASA 
llydrod for i 1 
;.>O 88 '4 +12 Gen. AS, post Fx rt. Reg 2 (L) Maalox 
femur with jewett Lax of Choice 
pinning 
L l 84 1 Unable Cerebral AS with Reg 4 (:') Pavabid 
Exp. possible ASA 
Parkinsonism Lax of Choice 
Bactrium 
22 94 3 +17 ASHD Reg 8 (3) Lanoxin, IJiP1etanc 
La six, Tyl L'DO I 
:n 98 3 +3 Arthritis, HCVD Lo 13 ((>) Indoc in 
controlled, ASCVD Chol Aldori l 
anemia Las ix 
Tylenol 
24 71 7 Unable ASHD Reg 4 (1) Tylenol 
Exp. Premarin 
2 r_; 84 4 Unable ASHD Reg 11 (5) Lax of Choi"" 
Diuril 
Pavabid 
Anacin 
l6 91 6 +12 ASHD, Fx left hip Reg 5 (3) Lax of Choice 
wit 11 pinning, Buffer in 
osteoporosis, Darvon fiS 
confused and Thorazine 
disoriented 
L7 83 3 +2 Arthritis, ASHD Reg 5(3) Doxidan 
Ceres pan 
28 85 3 +ll:; confused, disoriented, Reg 2 (1) ASA 
hypertension, Darvon 
osteoarthritis, 
vascular senility 
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Facility B (Continued) 
Drugs with 
Patient Years in Weight No. of Reported 
No. Age Facility + or 
-
Diagnosis Diet Drugs Interaction 
29 88 1 +l Very confused, cerebral Reg 3 (1) None 
AS, CBS, Fx left hip, 
left mastectomy 
30 82 3~ -2 Senile, disoriented, AS, Soft 5(2) ASA 
post colostomy Darvon 
31 80 4 Unable Confused, disoriented, Lo 7 (4) Lanoxin 
ASHD, post hip Fx, Na Pav a bid 
osteoarthritis Darvon 65 
Aspirin 
Las ix 
32 68 3 -19 Psychotic, Reg 6(3) Chloral Hydrate 
hypothyroidism Tylenol 
MOM 
33 86 9~ Same Senile, disoriented, Reg 4 (3) ASA 
cerebral AS, arthritis, Lnx of Choice 
cortical atrophy 
34 91 1 +14 Confused, ASHD, post Reg 8 (4) Pav a bid 
Fx rt hip, left Darvon Cmp. 6S 
inguinal hernia Tylenol 
15 91 l~ +9 Senile, deterioration, Reg 7 (4) Digoxin 
confusion, post Tylenol 
coronary, post hip Fx 
36 97 zi, Unahle Aortic stenosis, AS Reg 5(1) Lanoxin 
Exp. aneurysm of the Tylenol 
thoracic aorta, Fx 
rt hip with Jewett 
nailing 
37 87 l\o Unable ASHD, CVD, recent Lo 13 (2) Tylenol 
stroke, memory Na Kl or Vess 
impaired Decadron 
Lanoxin 
Lax of Choice 
38 62 6 +'l disoriented, AS, OBS Reg 5(4) MOM 
Ducolax 
39 93 Sam(' 1\.SCVD, CIIF controlled, Lo 5(2) Cournad in 
severe varicose veins Na Lanoxin 
Las ix 
MOM 
Darvon 
!10 88 1 -1'~ Fx rt. hip, alert Reg 3(2) ASA 
41 85 3i, Sn me Confused, post Fx hip Reg 6(6) ASA 
& pelvis, AS, 
arthritis, colitis 
42 79 4\c> Same CBS, ASHD, poi>t Fx 1000 6(2) Pavabid 
hip--aglta ted easily cal Chloral hydrate 
4J 86 -HI ASH!J with coronary Reg 8(4) Tofranil 
artery insufficiency, Lanoxin 
senile Lax of Choice 
ASA 
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Facility E (Continued) 
Drugs with 
Patient Years in Weight No. of Reported 
No. i\ge Facility + or - Diagnosis Diet Drugs Interaction 
44 84 212 Unable ASHD, OBS, mild diabetes Reg 1(1) None 
rnellitus, confused, 
agitated, disoriented 
45 84 1 Unable Parkinsonism, CVA Reg 7 (2) Atromid 
Exp. Dialose 
Zylopri.n 
46 97 411 -4 Gen. AS, post CVA, Reg 6(4) Gere span 
oriented to time and MOM 
place Darvon 65 
1;1 91 1 +111 Deg. joint disease, 1500 6(0) MOM 
mild diabetes cal Mineral Oil 
Purodigin 
48 80 2'-2 Unable CVA, ASHD with ao rti.c Soft 8 (4) Aldomet 
stcnosis and insuf- Las ix 
ficiency, pernicious Lax of Choice 
anemia, recurrent Tylenol 
urinary infection, Darvocet N 100 
confused and depressed 
49 73 1 Unable CVA, rt side paralysis Reg 7 (2) Lanoxin 
Exp. Elavil 
Tylenol 
so 73 1 -7 AS, CBS, Fx left hip, Reg 8(2) Zyloprin 
Gout Aldactazide 
Dialose 
Chloral Hydrate 
Darvon 
Tofranil 
51 83 1 Unable Cerebral AS, Reg 6(2) Aventyl 
M Parkinsonism, ASA 
decubitus ulcer 
Fat·il.ity C 
P.1Llent Years in Weight 
No. Age Facility + or - Diagnosis 
2 
3 
4 
5 
6 
7 
8 
') 
10 
11 
13 
81 
82 
f>S 
59 
93 
86 
93 
85 
87 
95 
78 
86 
86 
1 
1 
6 
13 
5 
2 
] 
112 
5 
7 
412 
Unable 
~~xp. 
-3 
Confused, adv. AS, AS 
dementia 
AS, Osteoporosis, 
Senile 
Unable Psychosis, ca skin, 
L side face 
+15 
MR, osteomylitis of 
left hip, hernia 
Acute depression, 
aphakic rt eye, 
glaucoma rt eye 
+l AS, senility 
Unable Fx rt. femur 
+5 AS, arthritis 
-12 Senile, diabetes 
mellitus, aortic 
stenosis, peripheral 
vascular disease 
Unable Mild confusion, 
Exp. senility, mild 
nutritional anemja 
Unable AS, CHS, arthritis 
Unable AS, ASHD with com-
Exr. pensated CHF 
diverticulosis, 
Pnrkinson's disease 
Unable Post CVA, left 
hemiplegia, CBS, 
diverticulosis 
Diet 
Soft 
Ne). of 
Drugs 
5(3) 
Bland 13(3) 
Reg 6(5) 
Reg 3(2) 
Drugs '.Jith 
Reported 
Interaction 
Esidrex 
Darvon 65 
Maalox 
Premarin 
Darvon 65 
Chloral Hydrate 
Pavabid 
MOM 
Thorazine 
MOM 
ASA 
Empirin 113 
MOM 
ASA 
Soft 11 (0)- Diamox 
Tofranil 
Reg 
Pur-
eed 
Lo 
Salt 
1500 
cal 
Reg 
12(7) 
8 (5) 
9(5) 
5(2) 
10(6) 
Pur- 4(3) 
eed 
Bland 12(5) 
Pur- 8{4) 
eed 
Lo 
Res 
Buffer in 
MOM 
ASA 
Darvon 65 
Las ix 
Butazolidin 
Kaochlor 
Lax of Choice 
Dialose 
ASA 
MOM 
Pavabid 
Lanoxin 
MOM 
ASA 
Darvon Pl 65 
Chloral hydrate 
Lax of Choice 
ASA 
Lanoxin 
MOM 
lluf fer in 
Colace 
Ascriptin 
l\actrim 
Darvon N 
Tylenol 
Darvocet 
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ll5 
Facility c (Continued) 
Dru~s with 
Patient Years in Weight No. of Reported 
No. Age Facility + or - Diagnosis Diet llrugs Interaction 
14 79 1 Same ASHD, Fx rt hip, CVA 1500 9(5) Diupreqs 
rt hemiplegia, cal Pav a bid 
tracheotomy Demerol 
Phenaphen 
Darvon 65 
MOM 
15 87 4 +5 ASHD, dementia, 1400 5(3) Phenobarbital 
diabetes mellitus, ca 1 MOM 
ep.ilepsy La six 
ASA 
16 66 1 f-5 Mentally confused, ca Soft 5(2) MOM 
of rectum with metases, ASA 
cerebral AS, colostomy 
17 81 1 -4 Fx L knee cap, post Reg 2 (1) Coumadin 
pneumonia, Tylenol 
thrombosis L deep vein 
18 82 3~ Unable CVA with h<'miplegia, 1200 13 (9) Ser-ap-es 
diabetes, speech cal MOM 
impaired due to stroke Phenobarbital 
Emp irin 
.'I ASA 
! 19 88 12 Unable AS, CHF, CVA, adv. OBS, 1800 7(2) Lanoxin 
Exp. comatose cal Pavabid 
tube Acetomenophen 
20 86 9 Unable ASHD, senility, dis- Soft 4(2) Las ix 
oriented, Glaucoma ASA 
21 77 2~ Same AS, AS dementia, Reg 13 (8) Aldomet 
hypertension Las ix 
Lax of Choice 
ASA 
Empirin llJ 
22 81 6 -16 AS dementia, ASHD, Reg 4(1) Digoxin 
disoriented ASA 
Hy drochlorthiaz ide 
Dioctyl Sod iurn 
Sulfoccinate 
23 89 7 +10 Hypertension, CBS, Soft 14 (7) Digoxin 
cerebral AS, Lo MOM 
depression Salt Ducolax 
Darvocet 
24 76 5 Unable Reticular cell Lo 22(10) Digitoxin 
Exp. .sarcoma, CHF, Na Prednisone 
cerebral AS Las ix 
Aldactfazide 
Coumadin 
Pav a bid 
K-Lyte 
Lax of Choice 
Tylenol 
Empirin 113 
Zyloprin 
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Facility c (Co11Linued) 
Drugs with 
l'atient Years in Weight No. of Rerorted 
No. Age Facility + or - Diagnosis Diet Drugs Interaction 
25 49 12 +52 Epilepsy, brain ~ttrgerv Reg 8 (4) Las ix 
performed, '" ithdrawn, Lax of Choi ct· 
mental deterioration ASA 
Dilant in 
Phc·nob1'!rbit0l 
26 90 3 Unable Disoriented, Fx L hip, Soft 7 ( 4) Empi.r j n 113 
Exp. AS, adv. ASIID Thorazine 
ASA 
Lan ox in 
Doxidan 
27 83 2 Unable Post TUR, senilily Reg 3 (2) Aldomet 
Exp. Thorazine 
28 91 1 Unable Diabetes mellitus, 1400 11 (8) Crystodigin 
ASHD, hypertension cal Phenobarbitol 
Butazolidin 
Bufferi n 
MOM 
Empirin 113 
Diupress 
Laslx 
29 79 2 -9 Fx rt hip, ASHD, Reg 6(5) Lax of Choice 
hypertension Aldomet 
Empirin 
Darvon Cmpd 65 
30 101 1l Unable AS, inguinal hernia Reg 9(3) ASA 
Exp. rt, arthritis Darvon 65 
Dyazide 
MOM 
31 72 6 -23 CBS, AS, very poor Reg 7 ( 4) MOM 
memory, chronic Phenobarbitol 
alcoholism 
pancreatit is 
32 89 l Unable ASHD with heart Soft 7 ('i) Lanoxin 
Exp. failure, old HI, MOM 
pneumonia Empirin 113 
Las ix 
Phenobarbital 
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r• '". i J i 1. y 11 
Drugs 1vith 
Par ie11 l t<"ars in Weight No. of Reported 
No. Age Facility + or - Diagnosis Di.,t Drugs Interaction 
76 212 Unable ASHD, MR, hyster<'ctomy Reg l(O) None 
Exp. (ca) 
2 86 112 -6 ASllD, OBS, Reg 4 (0) Ser-ap-es 
hypertension, senile Lanoxin 
88 +:ZS ASHD, OBS, Fx L hip, Soft 1, (J ) Crystodigin 
disoriented, MOM 
osteoporosis Darvon fJS 
4 44 5 -2 Birth injury, dorsal Soft 10(5) ASA 
scoliosis, mute 
5 46 6 UnabJe Incomplete quadraplegia, Reg ') ( ]_) Dorbantvl 
1 mn. Blind L eye, cellulitis Las ix 
-8 perineum, iliostomy, ASA 
chronic cystitis 
6 87 
.l "2 +7 Hypertension, Lo LJ (6) Ser-ap-es 
osteoarthritis, Na Tylenol 
lumbar spine, deg. M0:-1 
cervical disc syndrome Fiorinal 
Anacin 
7 86 1~ +13 Hypertension, ca L Lo 8 (4) Gelusil 
mastectomy, Salt 
conjunctivitis 
8 44 3 +2 Rheumatoid arthri tL;, Reg 5(2) Dilan tin 
osteoporosis, iron Phenabarbitol 
def. anemia, l'x L Surf ax 
femur, Duodenitis Da rvoce t N-J OU 
9 74 L'2 f-6 Pneumonia, active Lo 3(0) None 
gastric ulcer Ca 
Hi 
Fiber 
10 74 5 +6 ASHD, OBS, 1200 8 ( 3) Lanoxin 
osteoporosis, cal Ila rvon 
osteoarthritis of Tylenol 
spine, acute 
rhinitis, diabetes 
mellitus 
11 78 l Unable Bilateral AK amputat .Lon, Reg 4 (0) Co.Lace 
3 mo. CVI, ASCVD, periphera.l Hydrodiuril 
+'1'; va;;. disease Kcl Elixir 
l2 71 2 Unable Hypertension, CVA, Soft 4(2) Papv.erinc 
3 IHO ~ cellulitis L leg, rt. Ser-ap-es 
+4 inguinal hernia MOM 
ASA 
LJ 78 7\ -4 AS, COPD, PVD, BPH, Soft 8 (2) Digoxin 
Pulmonary TB (inactive) Lo Hydrod iur i 1 
Salt Kcl Elixir 
Dorbantyl 
Tylenol 
Facilil.y D (Continued) 
Patient 
No. 
14 
15 
16 
17 
18 
l.9 
20 
21 
22 
24 
25 
Years in Weight 
Age Facility + or - Jliaguosis 
6 7 1 Unable CllF, ASHD, 
79 
84 2 
68 2 
3 
67 1 
2 
7l 2 
77 l 
79 4':; 
82 
Exp. ost~oarthritis, 
Unable 
Exp. 
Unable 
3 mo. 
+6 
Unable 
Exp. 
Unilble 
3 1110' 
+·.i 
Un ab l <' 
M 
lJnabl.e 
M 
Unable 
+6 
Unable 
E>:p • 
+l 
diabetes, paranoid, 
schizoohrenia 
CHF, Ol:lS marked 
senility, Jeg. 
osteoarthritis, 
L sjde paralysis 
Hypertension, COl'D, 
arthritis, edema, 
blind L eye 
Nephrectomy, 
azotemia, CVA with 
L side paralysis, 
l1yp~rter1sinn 
Deg. CNS, scitcs, 
multiple sclerosiH, 
hJatus her11i.a 
ASHD, OBS, di.snrientc·cl, 
2nd and .1rd degree' 
burns, rheumato:id 
arthritis 
Diabetes mcllitus, 
hypertension, /\SHD, 
OBS, L vent 
hypertrophy, 
senile dementia 
COPD, OBS, ASHD, cla·. 
cystitis, ncute 
bronchitis 
AS!ID, COPD, OBS, 
Jehydrc4 tion, 
arrested TB 
ORS, /\SHD, AS, 
aphakia bilateral 
Osteoporosis, ASHD, 
ORS, statis edema, 
dPhydration, L 
mastectomy 
Diet 
LSOO 
ral 
2 gm 
Na 
Lo 
Fat 
Reg 
1500 
cal 
Soft 
Reg 
1600 
cal 
Sof l 
Reg 
79 4 Uuable Aeute gastroenteritis, 1800 
J mo. acute CHF, diabetes, cal 
+20 cystitis, bladder 
calculi, L renal tumor, 
cerebral apoplexy with 
L hemiparcsis 
Ko, nf 
J1n1,~·· 
h{O) 
'l(J) 
I ( 1) 
I 0 (4) 
l (!) 
l( L) 
2(1) 
J(l) 
4(1) 
6(3) 
lJ (1) 
Drug·' "ilh 
Ke ported 
lntcr<:.1c tion 
Dcgoxi.n 
l'cl Uixir 
L:1six 
Co lac<' 
Aspirin 
Tndoc in 
Pavabid 
Darvon 65 
Tylenol 
Lanoxin 
l':i.h:ila te 
Di ~:ox in 
ASA 
Surf ax 
PIH·naphen 
T) lennl 
Dw·olax 
/\SA 
ClJlace 
'!UM 
Tvleno1 
~JOM 
Tvlenol 
Mineral Oil 
Mml 
La six 
Cldoi·al Hydrate 
ASA 
MOM 
Lanoxin 
Hvdrodiuri.l 
Koan Cl 
Aldomet 
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Facility n (Continued) 
Drugs with 
Patient Years in Wl·ight No. of Reported 
No. Age Facility + or - Diagnosjs Dkt Drugs Interaction 
26 85 1 Same Ml, AS, CHF, ASHD, l\eg h(2) Lanoxin 
angina pectoris, Las ix 
senility Lcix of Choice 
'27 72 l~ +3 Disoriented, OBS, ,\S, Put:"- 1(0) Tylenol 
chronic pylonephritis, eccl 
acute cystitis, 
multiple trauma with 
multiple Fx ribs and 
pulmonary contusion 
28 49 5 Unable ASHD, hypertension, 1200 7(1) Aldomet 
Exp. diabetes, chronic cal Digoxin 
renal failure, hypo- Las ix 
glycemic reaction Apresoline 
29 82 2l:i Unable ASHD, OBS, TIA, acute Pur- 2(0) Aldomet 
Exp. urinary tract infect ion eed Macrodantin 
30 81 ll:i -12 ASHD, COPD, chr. UTI, 2 gm 6 (4) Pav ab id 
OBS, acute cystitis Na Lanoxin 
Soft Tylenol 
31 50 7~ +3 MR, schizophrenia, Reg 9 (3) Las ix 
paranoid type, Deg. Avoid MOM 
arthritis Sweets 
J2 72 2 -18 ASHD Soft 6(2) Pavabid 
Lanoxin, ASA 
33 76 21.:i +30 ASHD, COPD with acute Soft 0(0) None 
bronchitis, 
osteomyeli.tis, acute 
cellulitis 
'J4 71 3 -8 ca throat and lung, Reg 5(3) Tylenol 
COPD, OBS, AS, 
obstipation 
Facility E 
Patient 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15' 
16 
Age 
83 
64 
81 
84 
73 
86 
84 
51 
73 
40 
81 
84 
91 
77 
'89 
84 
Years in 
Facility 
New 
Facility 
Open 
June 
1976 
Weight 
+or -
Unable 
M 
Diagnosis 
CHF, CBS, old burn 
right hand 
CVA, juvenile diabetes, 
CHD, hypertension 
Unable CBS, diabetes 
M 
Unable 
M 
Unable 
M 
Unable 
M 
+4 
Same 
Unable 
M 
Unable 
ASHD, arthritis, L hip 
Fx, colitis, 
hypertension, 
hemmoroids 
Post-op Fx rt hip, 
hysterectomy, 
thrombus neck 1962 
Gen AS, back injury, 
disorientation 
ASHD, adv. rheumatoid 
arthritis, osteo-
arthritis 
Post-op removal rt 
hip, prosthesis, 
osteoarthritis 
CBS 
Diabetes, MS 
-11 ASCVD, senile 
Unable AS, CBS, CVA 
M 
Unable Mental confusion 
Exp. weakness 
-15 AS, hypertension, 
arthritis, diabetes, 
diverticulitis 
Unable ASHD, angina pectoris, 
mild confusion, 
diverticulosis, 
dizziness 
-1 Gen AS cerebral and 
Diet 
Reg 
1800 
cal 
1800 
cal 
Lo 
Salt 
Reg 
Soft 
Reg 
Bland 
113 
Reg 
1800 
cal 
Reg 
Reg 
Pur-
eed 
1500 
cal 
Reg 
1200 
coronary, hypertension, cal 
diabetes mellitus, 
confused 
No. of 
Drugs 
7 (0) 
11 (3) 
4(1) 
5(2) 
8 (1) 
7 (11) 
1 (5) 
4 (1) 
5(1) 
1 (0) 
3(1) 
3(0) 
4(0) 
3 (2) 
6(0) 
11(3) 
Drugs with 
Reported 
Interaction 
Purodigin 
MOM 
Aldomet 
Lanoxin 
Aldactazide 
Aprensoline 
Tylenol 
Eutron 
(MAO Inhibitor) 
Digoxin 
MOM 
Phenapht·n 
Lanoxin 
Tylenol 
Crystodigin 
Aldomet 
Pavabid 
ASA 
Tylenol 
Lax of Choice 
None 
Las ix 
Chloral Hydrate 
Crystodigin 
Las ix 
Dilantin 
None 
Ser-ap-eil 
Tylenol 
Digitoxin 
Pavabid 
Aldomet 
Las ix 
Dorbantyl 
120 
121 
1·aciUty F. (Cont i.nued) 
Drugs w L l h 
l'atient Years in Wc;ight No. l) f Report eel 
No. Age Facility + or - Diagnosis Diet Drugs 1nternctiPn 
i7 76 Unable ASHD, arthritis Reg 9(0) Digoxin 
M Kaochlor 
La six 
Premarin 
18 35 Un;iblc Severe MR, club feet Pur- 10(3) Dilantin 
M bilateral, decuhitus on eed Klorvess 
coccyx area PhenobarbHPJ 
Tylenol 
Lax of Choir(' 
19 93 Unable CBS, AS, Fx pelvis Reg 5(2) Ampicillin 
M Ducolax 
20 71 +8 AS, CHF, anxiety, Lo 8(4) Tofranil 
depression, Salt Lanoxin 
osteoarthritis ASA 
Lax of Choice 
Tylenol 
21 84 +3 CBS, AS, CHF, Lo 7 (2) HydrodiuriJ 
arthritis, Salt Lanoxin 
hypert,ension Aldactone 
ASA 
Lax of Choice 
22 77 -4 ASHD, CBS, several Reg 7(4) Aldoril 
small CVA's, mental ASA 
confusion, Lax of Choice 
hypertension Chloral Hydrate 
23 74 +6 Psychosis, AS, gross Reg 5(3) Thorazine 
tumor, rt upper Lax of Choice 
extremity ASA 
Gelusil 
24 69 -3 MR, ASHD, AS Reg 4(2) Pavabid 
Thorazine 
Lax of Choice 
ASA 
25 67 +7 Paranoid Schizo- Reg 5 (1) Thorazine 
phrenia, hypertension, Colace 
pyorrhea, constipat i <lll ASA 
26 1, 5 +2 Severe MR Reg J(:>) ASA 
Lax of Choice 
:!7 b4 Unable MR, diabetes, 1500 4(2) Lax of Choice 
M hypertension, obesity cal ASA 
:rn 89 Unable AS, CBS, CHF, Pur- 12(0) L-Dopa 
Exp. Parkinsoni.sm eed Lanoxin 
Las ix 
Ampicillin 
29 59 -18 Psychosis, surgery Reg 4 (2) Thorazine 
for hernia Lax of Choice' 
30 99 Unable AS, CP Reg 2 (2) ASA 
Lax of Choice 
122 
F;idl ity E (Co111 inued) 
---------
Drug~ \\d l Ii 
Pa L..i e11t Yv.-irs in Weight No. of RepurtC'<l 
No. Age F;icility + or - Diagnosis Diet Drugs [ntc'raction 
'll 63 Unable Cirrhosis, emphysema, Salt 7 (3) Aldactone 
M ascites, umhilical Pree A~;A 
hernia 
12 98 +7 CHF, ASHD Soft 10(3) MOM 
Las ix 
L;rnoxin 
Aldaetazide 
Zyloprin 
Aspirin 
'l3 84 +7 Cl:IS, dog bite with Reg 3(2) Thorazine 
skin graft L leg 
34 85 Unable AS, CBS, Fx L arm, Lo J ( 2) Hydroprc·.s 
mental illness, Salt Lax of Choice 
hypertension Tylenol 
35 75 Unable Senile brain Reg 4 (1) But:;Holidin 
syndrome /\script in 
36 84 +2 Gen. AS, alert, Reg 4 (0) Lax of Cho lee 
os teoa rt hr it is Doxi<lan 
I 
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